Mechanisms 990 items
The transfer protein itself: structure, the hydrophobic tunnel, kinetics, what inhibition does.
Studies
- The human CETP gene is cloned and sequenced for the first time (Nature 1987)
- Landmark genetic study explains why CETP inhibitors lower LDL cholesterol without reducing cardiovascular events (JAMA 2017)
- Eliminating liver Kupffer cells abolishes hepatic CETP expression and lowers plasma CETP, identifying their cellular origin for this protein (Hepatology 2015)
- The original discovery that hamster CETP uniquely drives one-way lipid flow from VLDL to HDL reveals CETP orthologs are not functionally equivalent across species (J Lipid Res 2014)
- Structural study proposes a tunnel-bridging mechanism for how CETP transfers cholesteryl ester between HDL and LDL (Nat Chem Biol 2012)
- First crystal structure of CETP reveals a 60-angstrom tunnel holding four lipid molecules (Nat Struct Mol Biol 2007)
- CETP expression multiplies atherosclerotic lesion area 7-fold in the new E3L.CETP mouse model (Arterioscler Thromb Vasc Biol 2006)
- HDL from CETP-deficient people shows 2- to 3-fold greater cholesterol efflux from macrophages via an ABCG1-dependent pathway enriched in LCAT and apoE (J Clin Invest 2006)
- The Hugh Sinclair Lecture synthesizes how ABCA1, LCAT, CETP, hepatic lipase, and PLTP together remodel HDL, naming CETP inhibition as a resulting therapeutic strategy (Atheroscler Suppl 2002)
- Cys-13, positioned near CETP's neutral-lipid-binding site, is identified as essential for irreversible inhibitor binding via mutagenesis and mass spectrometry (J Lipid Res 2000)
- A CETP-targeting vaccine cuts plasma CETP activity, raises HDL by 42%, and shrinks aortic lesions 39.6% in rabbits (Arterioscler Thromb Vasc Biol 2000)
- JTT-705, a disulfide-forming CETP inhibitor, raises HDL cholesterol and slows atherosclerosis in rabbits, the original discovery paper reports (Nature 2000)
- CETP and Cyp7a share an LXR-controlled sterol response, coordinating hepatic cholesterol ester catabolism with bile acid synthesis (J Clin Invest 2000)
- CETP expression cuts aortic lesion area 41% and restores HDL cholesteryl ester clearance in LCAT-transgenic mice with dysfunctional HDL (J Biol Chem 1999)
- Human CETP overexpression in hypertensive Dahl rats spontaneously causes combined hyperlipidemia, myocardial infarction and reduced survival, proving CETP can be proatherogenic (Nat Med 1999)
- LTIP, not CETP itself, explains why cholesteryl ester transfer favors HDL over LDL, overturning a long-held assumption (Arterioscler Thromb Vasc Biol 1999)
- Modeled on BPI's crystal structure, a proposed CETP mechanism has C-terminal residues 461-476 forming a helix that gates lipid entry into a hydrophobic pocket (Curr Opin Struct Biol 1998)
- An antibody blocking CETP-mediated lipid transfer sharply cuts HDL cholesteryl ester uptake by human adipocytes, revealing a direct CETP-dependent route into fat cells (J Biol Chem 1997)
- CETP incubation shrinks reconstituted HDL from 9.4 to 7.8 nm while raising particle count 50%, the first direct evidence of CETP-driven particle fusion (J Biol Chem 1997)
- Purified recombinant CETP acts as a lipid carrier with Km of 700 nM for LDL and 2000 nM for HDL, establishing its core kinetic mechanism (Biochem J 1996)
- Exon-9-deleted CETP mRNA yields an inactive protein, while hypercholesterolemia and development favor full-length transcript accumulation (J Biol Chem 1996)
- In mice, whether CETP protects against or promotes atherosclerosis depends entirely on triglyceride status, protective only when hypertriglyceridemic (J Clin Invest 1995)
- Two independent inhibitors reveal separate CETP binding sites for cholesteryl ester and triglyceride transfer, uncoupled in vivo (J Biol Chem 1995)
- K233 and R259 are essential CETP residues for lipoprotein binding, conserved across the CETP/PLTP/LPS-binding-protein gene family (Biochemistry 1995)
- CETP binds preferentially to the edge of nascent discoidal HDL particles, with affinity boosted 3- to 10-fold by cholesteryl ester or cholesterol content (J Biol Chem 1995)
- A comprehensive Annual Review of Biochemistry synthesis by Alan Tall concludes CETP is dominantly antiatherogenic in vivo despite lowering HDL cholesterol (Annu Rev Biochem 1995)
- CETP enriches HDL with triglyceride, accelerating lipolysis-driven apoA-I shedding and shortening apoA-I half-life, explaining low HDL in CETP mice (J Biol Chem 1994)
- CETP shrinks HDL from 10.3 to 7.6 nm and increases apoA-I catabolic rate 35% in hypertriglyceridemic transgenic mice, revealing the kinetic basis of low HDL (J Clin Invest 1993)
- Landmark Nature paper shows CETP-expressing transgenic mice develop far worse atherosclerosis than non-expressing controls (Nature 1993)
- Deletion mutagenesis pinpoints residues Phe463 to Leu475 as essential for both TP2 antibody binding and CETP's neutral-lipid-transfer activity (J Biol Chem 1992)
- CETP crossed with human apoA-I transgenic mice deepens HDL cholesterol loss to 66%, revealing an enhanced human-CETP/human-apoA-I interaction (J Clin Invest 1992)
- Baculovirus-expressed CETP deletion mutants pinpoint residues Phe-Leu-Leu-Leu (454-457) as essential for lipid transfer, a motif shared with LCAT, LBP, BPI and other lipid-binding enzymes (Proc Natl Acad Sci U S A 1992)
- A 50% rise in CETP activity after probucol tracks plasma drug levels and inversely predicts the fall in HDL cholesterol (Eur J Clin Invest 1991)
- Linker-insertion mutagenesis maps three CETP regions essential for lipid transfer, at residues 48-53, 165, and 373-379 (Biochemistry 1991)
- An anti-CETP antibody fully blocks CETP-driven HDL3 size conversion, proving CETP drives structural remodeling beyond lipid transfer (J Lipid Res 1990)
- A neutralizing anti-CETP antibody eliminates all neutral lipid mass transfer in human plasma, while HDL serves as the main early LCAT substrate (J Clin Invest 1989)
- Neutralizing antibodies against the 74kDa CETP eliminate essentially all plasma cholesteryl ester and triglyceride transfer activity, proving CETP is the responsible protein (J Biol Chem 1988)
- The original isolation of the 74kDa human plasma CETP reveals a leucine-rich, highly hydrophobic protein specific for cholesteryl ester over triglyceride transfer (Proc Natl Acad Sci U S A 1987)
- CETP boosts HDL cholesteryl ester uptake into HepG2 liver cells 2.8-fold, the original demonstration of CETP-facilitated selective cellular cholesterol delivery (J Biol Chem 1987)
- Landmark purification establishes human CETP as a unique 74-kDa hydrophobic plasma apolipoprotein (J Biol Chem 1987)
- Human but not rat lipoprotein-deficient serum drives cholesteryl ester efflux from cultured arterial smooth muscle cells, implicating CETP in interstitial cholesterol removal (Biochim Biophys Acta 1985)
- Without CETP, LCAT activity stalls once cholesteryl ester reaches a 0.03 ester-to-lecithin ratio; CETP clears the product to sphingomyelin liposomes to keep LCAT running (Biochemistry 1980)
- Landmark 1978 paper reports the original isolation of the human cholesteryl ester transfer protein itself (Proc Natl Acad Sci USA 1978)
- The Morton lab introduces substrate-preference modification as a new paradigm for engineering CETP-targeting drugs (J Lipid Res 2015)
- CETP C-terminal peptides drive lipid particles from large aggregates into small micelle-like structures via disorder-to-order transitions, a proposed lipid-transfer mechanism (J Struct Biol 2014)
- A landmark review proposes the first comprehensive step-by-step molecular model of CETP action: sensing, penetration, docking, ternary complex, transfer, dissociation (J Lipid Res 2012)
- Molecular dynamics simulations reveal helix X of CETP as a lid gating lipid exchange with HDL (PLoS Comput Biol 2012)
- CETP expression halves atherosclerotic lesion area in non-diabetic LDL-receptor-deficient mice, but this protection disappears with diabetes, another context-dependence finding for the CETP paradox (APMIS 2005)
- A new liposome-based assay shows CETP transfer rate depends jointly on donor AND acceptor surface cholesteryl-ester content, with LDLs varying 1.8-fold in CE-presenting capacity (J Lipid Res 2003)
- Chemical labeling localizes an unpaired active-site cysteine, likely residue 333, whose modification sterically blocks CETP's cholesteryl-ester transfer activity (Chem Phys Lipids 2002)
- A novel transposon-based method sequences 5kb of CETP's 5' regulatory region, revealing a 5.7kb fragment drives far stronger transcription than the minimal promoter (Gene 1997)
- A new self-quenching BODIPY-cholesteryl-ester microemulsion assay enables simple fluorescence-based measurement of CETP activity in plasma (J Lipid Res 1993)
- CHO-cell expression and site-directed mutagenesis show all four potential N-glycosylation sites of CETP are occupied, explaining its glycoprotein doublet on SDS gels (Biochemistry 1993)
- C/EBP binds the CETP gene promoter and boosts its reporter-gene activity in liver cells, with C/EBP and CETP mRNA loss occurring in parallel in cultured hepatocytes (J Biol Chem 1992)
- Within three days, an atherogenic diet raises rabbit liver CETP mRNA 2.8-fold and plasma CETP mass 3.2-fold, while other liver mRNAs stay unchanged (J Clin Invest 1990)
- CETP retains lipid-transfer activity after protease fragmentation but not as isolated E. coli-expressed fragments, showing no independent catalytic subunit exists (J Biol Chem 1989)
- Chromatography, electrophoresis and immunoprecipitation together show apolipoprotein D and CETP are distinct proteins, resolving early confusion about CETP's identity (Biochim Biophys Acta 1981)
- Liver-targeted CETP expression improves glucose tolerance in female mice but worsens it and drives fatty liver in males (bioRxiv 2026)
- CETP expression preserves endothelial function in female mice via enhanced estrogen receptor-alpha and eNOS signaling, unlike its harmful effect in males (Am J Physiol Heart Circ Physiol 2023)
- Why raising HDL with CETP inhibitors did not help: evacetrapib and torcetrapib both boosted the harmful apoC3-containing HDL subspecies most (Arterioscler Thromb Vasc Biol 2022)
- ADCY9 and CETP show signs of having coevolved under sex-specific selection, offering a biological explanation for the pharmacogenomic signal of dalcetrapib (eLife 2021)
- Swapping hamster CETP for human CETP cuts HDL by 60% and boosts hepatic cholesterol 1.8-fold in a human-like hamster model (J Lipid Res 2021)
- Despite no direct LPS-binding activity, human CETP raises mortality in mouse models of endotoxemia and sepsis by impairing lipoprotein-mediated protection (J Lipid Res 2020)
- In female mice, CETP enables an estrogen-SHP pathway raising VLDL triglyceride production and, independently, an ERalpha pathway boosting liver fat oxidation (J Lipid Res 2016)
- CETP binds factor Xa and boosts prothrombinase activity, and the VTE-linked Gln451 variant shows five-fold higher thrombin generation than wild-type (J Atheroscler Thromb 2016)
- Human CETP transgenic mice show higher survival and lower IL-6 after polymicrobial sepsis, linked to reduced macrophage TLR4 and NF-kB activation (Mediators Inflamm 2016)
- Two CETP splice-affecting variants raise mortality and heart attack risk specifically in men, mechanism traced to liver mRNA splicing (PLoS One 2012)
- Discovery paper introduces evacetrapib, a potent CETP inhibitor that raises HDL cholesterol without inducing aldosterone or raising blood pressure (J Lipid Res 2011)
- Inflammatory macrophages selectively lose the LXR-driven induction of CETP seen in noninflammatory cells, even as ABCA1 and ABCG1 induction persist (Arterioscler Thromb Vasc Biol 2009)
- CETP discovered to protect mice against lethal bacterial endotoxin by dampening the inflammatory response (Shock 2008)
- Niacin raises HDL cholesterol by suppressing hepatic CETP expression, not by any CETP-independent route (Arterioscler Thromb Vasc Biol 2008)
- CETP expression boosts macrophage reverse cholesterol transport in mice via the LDL receptor pathway (Circulation 2007)
- Fenofibrate raises HDL cholesterol by up to 91% only in the presence of CETP, via a 72% reduction in hepatic CETP expression, in transgenic mice (J Lipid Res 2007)
- A chimeric anti-CETP vaccine shrinks aortic plaques by over 40 percent in cholesterol-fed rabbits (Life Sci 2005)
- CETP transgene expression reverses the cholesterol-raising effect of LXR agonists and instead lowers hepatic cholesterol while boosting biliary excretion in mice (J Lipid Res 2004)
- Human CETP expression completely prevents diet-induced atherosclerotic lesions in diabetic obese db/db mice (Arterioscler Thromb Vasc Biol 2003)
- ApoC-I identified as the natural CETP inhibitor carried on HDL (J Biol Chem 2000)
- Combining a CETP transgene with PLTP deficiency additively lowers HDL cholesteryl ester and apoA-I in mice, showing no functional redundancy (J Biol Chem 2000)
- CETP remodeling of HDL boosts SR-BI-mediated cholesteryl ester uptake 2- to 4-fold, synergizing with hepatic lipase in reverse cholesterol transport (J Lipid Res 1999)
- Liver-targeted antisense oligonucleotides against CETP suppress atherosclerosis in cholesterol-fed rabbits (J Biol Chem 1998)
- Oleate suppresses LTIP activity over 80%, unleashing maximal CETP-mediated lipid transfer between all lipoproteins including LDL (Arterioscler Thromb Vasc Biol 1997)
- First demonstration that liver-targeted antisense oligonucleotides against CETP lower LDL and raise HDL in cholesterol-fed rabbits (J Biol Chem 1996)
- ApoE or LDL receptor knockout raises hepatic CETP transgene expression eightfold, revealing a cholesterol-sensing mechanism independent of both (J Clin Invest 1996)
- ARP-1 acts as both repressor and activator of the CETP gene promoter depending on flanking sequence context, via a defined 105-bp regulatory element (J Biol Chem 1995)
- CETP-deficient humans clear LDL apoB faster, explaining their low LDL despite reduced apoB production (J Clin Invest 1995)
- ApoB/CETP double transgenic mice recreate a human-like lipoprotein cholesterol distribution on chow diet (J Lipid Res 1995)
- Deleting six carboxyl-terminal residues of CETP abolishes cholesteryl ester and triglyceride binding without affecting HDL association (J Biol Chem 1995)
- CETP expression suppresses hepatic LDL receptor mRNA dose-dependently, explaining apoB-lipoprotein accumulation (J Biol Chem 1993)
- Bulky hydrophobic residues Leu475, Phe471, Leu468, Phe461 and Phe454 on one face of a C-terminal helix drive CETP's cholesteryl-ester transfer activity, distinct from the antibody-binding face (J Biol Chem 1993)
- CETP is locally synthesized and secreted within the human brain, not just imported from plasma (Int J Clin Lab Res 1992)
- First human CETP transgenic mice show that active plasma CETP causally reduces HDL cholesterol (J Biol Chem 1991)
- CETP has dedicated binding sites for cholesteryl ester, triglyceride, and phospholipid that let it ferry lipids between particles (J Biol Chem 1988)
- Lipolysis products bind CETP directly to VLDL remnants and HDL, driving faster cholesteryl ester transfer (J Biol Chem 1985)
- Lipoprotein lipase and CETP together boost cholesteryl ester transfer 2 to 8 fold beyond CETP alone (J Biol Chem 1984)
- Reducing CETP activity with evacetrapib preserves memory in an Alzheimer's mouse model, independent of amyloid or tau markers (EMBO Mol Med 2026)
- CETP inhibitors reframed: from raising HDL to lowering atherogenic lipoproteins and improving glycaemic control, with obicetrapib the current lead (Circ Res 2026)
- CETP activity, but not mass, is independently linked to coronary disease in patients with high HDL cholesterol (Anatol J Cardiol 2026)
- A tunnel-like hydrophobic channel enables CETP bidirectional neutral lipid transfer, structurally distinct from other lipid-binding proteins (J Mol Graph Model 2026)
- CETP rs3764261 genotype modifies the HDL-C lowering effect of a vegetarian diet in 9,263 adults (Taiwan Biobank) (Front Nutr 2026)
- A mathematical model extends CETP-mediated triglyceride flux estimation to chylomicrons in postprandial lipemia (J Lipid Res 2025)
- CETP expression abolishes the atheroprotective effect of large HDL particles in mouse models of type 1 diabetes (Circ Res 2024)
- CETP expression in bone-marrow-derived immune cells reduces inflammatory features of atherosclerosis, helping explain trial failures (Biomolecules 2023)
- Serum amyloid A is required for CETP to promote atherosclerosis in mice, suggesting CETP inhibition may help patients with high inflammation (J Lipid Res 2023)
- A specific CETP isoform tracks disease severity and may help neutralize bacterial toxin in Gram-negative sepsis (Mol Med 2022)
- CETP expression in macrophages curbs mitochondrial oxidant production and dampens pro-inflammatory, cholesterol-laden phenotypes (Antioxidants 2022)
- Abdominal aortic aneurysm patients show 49% higher CETP activity and altered HDL cholesterol efflux compared with atherosclerosis controls (Front Immunol 2022)
- Hibernating brown bears raise CETP activity by 36% to stabilize HDL lipid composition and avoid atherogenic dyslipidemia (Sci Rep 2021)
- How ADCY9 and CETP might interact inside arterial macrophages to explain the genotype-dependent effect of dalcetrapib, with dal-GenE poised to test it (Circ Genom Precis Med 2021)
- Advanced mass spectrometry reveals that CETP is secreted in medium-large HDL and stays there, unlike LCAT which appears on HDL only after a delay (JCI Insight 2021)
- A human CETP minigene improves insulin sensitivity and reduces fatty liver in female but not male mice on a high-fat diet (Front Physiol 2021)
- Genetic and drug-based CETP inhibition preserves HDL and improves survival in sepsis, in humans and humanized mice (Circulation 2021)
- Swapping hamster CETP for human CETP in chow-fed hamsters humanizes their lipoprotein profile, cutting HDL up to 50% (J Lipid Res 2020)
- Genetic CETP inhibition doesn't touch particle-size-defined LDL-C the way statins do, but lowers remnant, VLDL and HDL-triglyceride content instead (PLoS Biol 2019)
- ApoF knockdown boosts CETP-mediated cholesterol ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters (J Lipid Res 2019)
- Evacetrapib raises large and medium HDL but cuts the functionally important preβ-1 HDL by 36%, a clue to why raising HDL-C didn't help (Atherosclerosis 2019)
- Mendelian randomisation upends the textbook story: the causal effects of CETP fall mainly on large HDL and small VLDL, not LDL, hinting anacetrapib works by cutting VLDL (Eur J Hum Genet 2019)
- First genome-wide association study identifies genetic determinants of circulating CETP concentration (Circ Genom Precis Med 2018)
- Mendelian randomisation links the CETP inhibitor target locus to lower abdominal aortic aneurysm risk (JAMA Cardiol 2018)
- Weight loss plus exercise normalizes the HDL lipidome, lowers CETP activity, and boosts cholesterol efflux capacity in metabolic syndrome (Arterioscler Thromb Vasc Biol 2018)
- A proteomic risk score could have flagged harm from torcetrapib within 3 months of ILLUMINATE, revealing unexpected immune and inflammatory effects (Circulation 2018)
- Anacetrapib lowers lipoprotein(a) by cutting its production rate 41%, not by speeding its clearance (ATVB 2017)
- Glucocorticoids downregulate CETP gene expression in macrophages, and doubling hydrocortisone dose lowers CETP activity and raises HDL size in patients (Eur J Clin Invest 2017)
- ACCENTUATE: evacetrapib beat ezetimibe and higher-dose statin on LDL-C and Lp(a), but also raised hsCRP, a clue to why ACCELERATE later failed (Atherosclerosis 2017)
- CETP redistributes the vasoprotective lipid sphingosine-1-phosphate from HDL to apoB lipoproteins, changing which signals it triggers (Arterioscler Thromb Vasc Biol 2017)
- Anacetrapib impairs endothelial function in CETP-transgenic mice despite raising HDL-C fivefold, while evacetrapib does not (Atherosclerosis 2017)
- Yamashita argues CETP inhibition may backfire by generating small dense LDL and downregulating hepatic SR-BI (Curr Opin Lipidol 2016)
- Arsenic trioxide independently raises CETP protein levels in liver cells while suppressing LXR-beta and cholesterol efflux (Chem Biol Interact 2016)
- Anacetrapib raises HDL apoA-I and plasma CETP levels by slowing their clearance rather than boosting their production (ATVB 2016)
- TA-8995 (obicetrapib) raises ABCA1-specific cholesterol efflux capacity by 28% and preBeta-1 HDL by 36%, showing functional as well as HDL-C gains (J Clin Lipidol 2016)
- Evacetrapib raises ABCA1-specific cholesterol efflux capacity and pre-beta-1 HDL, effects that statins alone do not share (JACC 2015)
- Anacetrapib lowers LDL-ApoB by accelerating its clearance, not by slowing its production (J Clin Invest 2015)
- Topoisomerase II inhibitors etoposide and teniposide activate hepatic CETP expression via LXR and boost reverse cholesterol transport in CETP transgenic mice (J Biol Chem 2015)
- Transgenic CETP expression nearly doubles run distance in obese female mice via increased muscle mitochondrial oxidative capacity and PGC-1alpha (PLoS One 2015)
- Anacetrapib dose-dependently shrinks atherosclerotic lesions by up to 92% and adds to the benefit of atorvastatin (Eur Heart J 2015)
- Fibrates and fish oil, but not corn oil, activate PPAR-alpha to raise hepatic CETP expression and plasma activity in transgenic mice (J Nutr Biochem 2014)
- Inhibiting secretory phospholipase A2 raises CETP activity via VLDL-apoE content, offsetting its antiatherosclerotic benefit in triple-transgenic mice (Arterioscler Thromb Vasc Biol 2013)
- Cysteine 13 of CETP is the key residue that lets dalcetrapib decouple cholesteryl ester transfer from HDL remodeling (Biochim Biophys Acta 2013)
- Dietary cholesterol dose-dependently drives osteoarthritis in CETP-humanised mice, and atorvastatin but not ezetimibe suppresses it despite similar cholesterol lowering (Ann Rheum Dis 2013)
- Bile-acid-activated farnesoid X receptor identified as a novel driver of CETP expression, explaining low HDL-C in cholestasis (J Lipid Res 2013)
- Niacin lowers plasma CETP mass 30% by reducing liver macrophage content, not by directly suppressing macrophage CETP expression (Biochem Pharmacol 2012)
- CETP protects against the rise in VLDL caused by reconstituted HDL infusion, resolving a mouse-versus-human discrepancy (J Lipid Res 2011)
- Framingham study finds plasma CETP activity has only minimal association with blood pressure change over time (J Hypertens 2011)
- Only dalcetrapib preserves pre-beta HDL formation and boosts fecal sterol excretion, unlike torcetrapib and anacetrapib (J Lipid Res 2010)
- Anacetrapib binds CETP reversibly while dalcetrapib binds covalently, explaining their different inhibitory kinetics (J Lipid Res 2010)
- Anacetrapib doubles HDL cholesterol and, unlike niacin, boosts cholesterol efflux per particle at high HDL levels (ATVB 2010)
- Torcetrapib impairs blood vessel dilation through a mechanism unrelated to CETP inhibition or HDL elevation, unlike a structurally different CETP inhibitor (J Cardiovasc Pharmacol 2010)
- CETP restores HDL cholesterol in SR-BI-deficient mice but fails to prevent atherosclerosis (Arterioscler Thromb Vasc Biol 2010)
- LXRalpha, not LXRbeta, drives human CETP transcription, confirmed in monkeys, human-CETP-transgenic mice, and HepG2 cells (Atherosclerosis 2010)
- LURIC study of 3,256 angiography patients finds low, not high, CETP levels predict mortality (Circulation 2010)
- CETP raises HDL triglyceride but leaves triglyceride production and clearance unchanged in APOE*3-Leiden mice (J Lipid Res 2010)
- Ciprofibrate boosts CETP gene expression and speeds cholesterol delivery to the liver in CETP-transgenic mice (Lipids Health Dis 2009)
- Berry anthocyanins raise HDL and lower LDL cholesterol via natural CETP inhibition in a placebo-controlled trial (Am J Clin Nutr 2009)
- CETP delays clearance of dietary fat by slowing triglyceride clearance and suppressing lipoprotein lipase (Biochem J 2009)
- CETP drives atherosclerosis mainly by raising VLDL-cholesterol, not by lowering HDL-cholesterol, in APOE*3-Leiden mice (Atherosclerosis 2009)
- Tesaglitazar lowers CETP mass and activity and halts progression of existing atherosclerosis in CETP-transgenic mice (Br J Pharmacol 2009)
- Rising VLDL-triglyceride from bexarotene drives CETP activity up and HDL cholesterol down (Endocrinology 2009)
- CETP expression reverses the direction of PXR agonism effect on HDL cholesterol, turning an increase in mice into a dose-dependent decrease (Biochim Biophys Acta 2009)
- The combined action of SAA, secretory phospholipase A2, and CETP remodels HDL during the acute phase response while preserving cholesterol efflux capacity (Arterioscler Thromb Vasc Biol 2009)
- Acute coronary syndrome reduces leucocyte CETP expression up to 6-fold, with recovery tracking reduced inflammation, confirmed in CETP transgenic mice (J Intern Med 2008)
- Apple polyphenols improve cholesterol distribution in hamsters by directly inhibiting CETP activity (Mol Nutr Food Res 2008)
- FXRalpha suppresses CETP gene expression by competing with LXRalpha at a shared promoter element (Mol Cells 2008)
- Adrenalectomy prevents the torcetrapib blood pressure rise, proving CETP inhibition itself is not the culprit (Br J Pharmacol 2008)
- CETP plasma levels are positively correlated with blood clotting speed, and recombinant CETP enhances prothrombinase activity, revealing a previously unknown procoagulant role (Thromb Haemost 2007)
- Complexing with spherical HDL protects CETP from mast cell chymase degradation, while CETP reciprocally protects discoidal HDL (J Lipid Res 2008)
- Atorvastatin's HDL-raising effect in mice requires CETP expression, proving statins work partly by suppressing CETP (Atherosclerosis 2007)
- Chronic CETP deficiency disrupts adipocyte lipid storage, revealing a novel intracellular role for CETP (J Biol Chem 2007)
- Bone marrow-derived CETP alone drives a proatherogenic lipid profile and 1.8-fold more atherosclerosis, and Kupffer cells supply half of hepatic CETP, in LDL receptor knockout mice (Circ Res 2007)
- In the Hoorn Study, high CETP concentration more than triples cardiovascular disease risk in women with Type 2 diabetes, with no such association in men (Diabet Med 2007)
- CETP expression protects SR-BI-deficient mice from diet-induced atherosclerosis by remodeling buoyant HDL toward normal density (Arterioscler Thromb Vasc Biol 2007)
- Dense genotyping of the CETP gene in over 2,000 people pinpoints a promoter SNP at position -4,502 as likely functional for HDL cholesterol (J Lipid Res 2007)
- A rapid 6-hour HDL subfractionation method reveals HDL has a dual role in oxidation: CETP-dependent prooxidant during VLDL oxidation, antioxidant during LDL oxidation (J Lipid Res 2007)
- CETP directly delivers HDL cholesteryl ester to the liver independent of SR-BI and LDL receptor pathways (Biochim Biophys Acta 2006)
- Adipose-specific CETP expression alone lowers HDL cholesterol and shrinks adipocytes in mice (J Lipid Res 2006)
- A DNA vaccine displaying a CETP epitope on hepatitis B core protein cuts aortic lesion area by 80.6% in a rabbit atherosclerosis model (Vaccine 2006)
- CETP expression cuts atherosclerotic lesion size 44% in testosterone-deficient mice (J Lipid Res 2006)
- CETP inhibition in rabbits blocks one HDL cholesteryl ester removal pathway but does not compromise overall clearance from plasma (Arterioscler Thromb Vasc Biol 2005)
- Torcetrapib binds CETP roughly 5-fold tighter to HDL, locking it into a nonproductive complex that blocks all major lipid transfer (J Lipid Res 2006)
- A high-fat monounsaturated diet blocks cholesterol from stimulating CETP by suppressing LXR-alpha expression, unlike a low-fat diet (J Lipid Res 2005)
- A CETP-epitope vaccine carried by heat shock protein-65 reduces aortic lesions by up to 30.8% in rabbits (J Cardiovasc Pharmacol 2005)
- ApoCI overexpression backfires as a CETP-blocking strategy by triggering compensatory CETP gene induction (Biochem J 2005)
- A moderate-expresser human-CETP transgenic rat model recapitulates female athero-resistance seen in humans (Atherosclerosis 2004)
- CETP moves HDL lipids into adipocytes without receptors or endocytosis, overturning the prevailing uptake model (J Lipid Res 2004)
- Probucol still lowers HDL cholesterol in humans with complete CETP deficiency, disproving its CETP-dependent mechanism (Atherosclerosis 2003)
- Streptozotocin-induced diabetes raises CETP mass and activity in transgenic mice, partly reversed by insulin (Can J Physiol Pharmacol 2003)
- LTIP steers CETP's lipid-transfer preference toward HDL3 while keeping HDL2 activity low and constant (J Biol Chem 2003)
- Garlic supplementation lowers CETP activity and shrinks atherosclerotic lesions in cholesterol-fed rabbits (Life Sci 2003)
- Sp1 and Sp3 transcription factors regulate the human CETP gene promoter through three binding sites, with the Sp1/Sp3 ratio determining their relative activity (J Lipid Res 2003)
- An Alu repeat represses and a CPF binding site activates the human CETP gene's distal promoter (J Lipid Res 2003)
- CETP expression halves aortic lesion area in ovariectomized mice, an atheroprotective effect blunted by estrogen therapy (J Lipid Res 2003)
- Expressing simian CETP in Fisher rats cuts HDL cholesterol by 48%, selectively depleting large apoE-containing HDL1 particles by 74% (J Lipid Res 2002)
- Meal-induced CETP activity redirects HDL cholesterol esters toward atherogenic VLDL-1 particles, rising 32-fold in type IIB hyperlipidemia versus healthy controls (J Lipid Res 2002)
- High plasma CETP does not speed reverse cholesterol transport in vivo despite raising liver cholesteryl ester uptake (Atherosclerosis 2002)
- LCAT deficiency posttranscriptionally suppresses plasma CETP levels, likely via loss of HDL (Arterioscler Thromb Vasc Biol 2002)
- PLTP, not CETP, drives generation of pre-beta HDL in transgenic mice, a 3-fold rise versus CETP-only or wild-type animals (Biochem J 2001)
- CETP found directly inside atherosclerotic plaque foam cells, revealing an anti-atherogenic role in cholesterol removal at the earliest step of reverse transport (Atherosclerosis 2001)
- CETP-LDL associations are strongest with saturated fat, hinting at why it drives atherogenesis (J Lipid Res 2001)
- Small-for-gestational-age neonates have lower CETP mass but higher cholesteryl ester transfer, possibly explaining later CHD risk (Metabolism 2001)
- Immunohistochemistry and in situ hybridization localize CETP production to smooth muscle cells within the human aortic intima and media (Atherosclerosis 2001)
- Bile-acid feeding represses hepatic CETP expression in male mice but induces it in female mice, revealing a sex-specific regulatory response tied to LRH-1 (J Biol Chem 2001)
- Four CETP-transgenic mouse strains show lipoprotein cholesterol shifting between HDL and LDL in an allelic dose-dependent manner across a 2.9 to 37.4 microg/ml CETP range (Biochem Biophys Res Commun 2001)
- Rising triglycerides redirect CETP-mediated cholesterol transfer from LDL toward VLDL1, fueling small dense LDL in type 2 diabetes (Arterioscler Thromb Vasc Biol 2001)
- LDL oxidation redirects CETP transfer backward, pulling cholesteryl ester out of LDL and into HDL instead (Clin Chim Acta 2001)
- Combining apoA-II and CETP transgenes triggers massive VLDL overproduction in mice (J Lipid Res 2001)
- Structure-activity studies identify JTT-705 as the optimum CETP inhibitor among a series of disulfide and thioester compounds (J Med Chem 2000)
- In a 24-week RCT, French-press coffee raises CETP activity up to 18% within two weeks, preceding the later rise in LDL cholesterol (J Intern Med 2000)
- Infants have naturally high CETP activity that is unaffected by thyroid hormone status, unlike prior reports (Metabolism 2000)
- Chronic growth hormone replacement lowers CETP activity alongside LCAT, improving the lipoprotein profile (J Lipid Res 2000)
- Atorvastatin preferentially reduces CETP-mediated cholesteryl ester transfer from HDL to the largest VLDL subfraction (Arterioscler Thromb Vasc Biol 2000)
- VLDL-bound lipoprotein lipase boosts CETP-mediated cholesteryl ester transfer partly independent of its lipolytic action (J Lipid Res 1999)
- A refined CETP epitope map, built from eight monoclonal antibody binding sites, supports a BPI-based structural model of CETP's overall conformation (Protein Sci 1999)
- An apoE-peptide carrier delivers antisense DNA into cell nuclei, cutting CETP mRNA over 50% and CETP activity to 53.8% of control in CHO cells (Arterioscler Thromb Vasc Biol 1999)
- Combined LCAT and CETP action in vitro converts VLDL and LDL into the small, dense particles seen in hypertriglyceridemia (Atherosclerosis 1998)
- Beta-adrenergic stimulation drives CETP secretion from hamster adipose tissue through a cAMP pathway (Atherosclerosis 1998)
- Probucol raises CETP mRNA up to 221% and boosts cholesterol efflux 354% in a dose-dependent manner in CETP-transfected hamster ovary cells (Biochim Biophys Acta 1998)
- CETP preferentially transfers cholesteryl ester over triglyceride when interacting with HDL, independent of its HDL binding (J Biochem 1998)
- Expressing simian CETP in obese diabetic KKAy mice cuts HDL from 159 to 25 mg/dl by enriching HDL with triglyceride 10-fold (Am J Physiol 1998)
- Blocking apoB mRNA editing doubles plasma apoB-100 and shifts cholesterol from HDL to LDL specifically in CETP transgenic mice (Arterioscler Thromb Vasc Biol 1998)
- CETP preferentially enriches VLDL1 with cholesteryl ester during postprandial lipemia, marking it as atherogenic (Arterioscler Thromb Vasc Biol 1998)
- Plasma CETP activity rises in hyperthyroidism and falls in hypothyroidism, correcting with treatment (J Clin Endocrinol Metab 1998)
- CETP expression suppresses liver LDL receptor mRNA in ApoB/CETP double transgenic mice, reversible by oncostatin M (Arterioscler Thromb Vasc Biol 1997)
- Human apoA-I transgenic mouse HDL lacks the heat-labile inhibitor that normally caps CETP activity at high HDL levels (J Biol Chem 1997)
- Growth hormone excess raises CETP activity and shifts LDL toward the small dense subfraction in acromegaly (Atherosclerosis 1997)
- CETP accounts for 15.2% of HDL cholesterol variation in hypertriglyceridemic men, more than LCAT, lipases, or triglycerides individually (Arterioscler Thromb Vasc Biol 1997)
- CETP predicts low HDL cholesterol independent of lipoprotein lipase in hypertriglyceridemic men but not in normotriglyceridemic men (Arterioscler Thromb Vasc Biol 1996)
- LpA-I:A-II is an efficient CE donor to triglyceride-rich lipoproteins despite low CETP affinity, fenofibrate raising HDL cholesterol 28% without changing CETP mass (Arterioscler Thromb Vasc Biol 1996)
- 13-cis-retinoic acid strongly activates CETP through its negatively charged carboxylic group (Eur J Biochem 1996)
- Lipoprotein lipase deficiency cuts cholesteryl ester transfer despite normal CETP mass, restored by adding lipoprotein lipase (J Lipid Res 1996)
- HDL3 electronegative charge density, peaking near minus 2,200 esu per square centimeter, governs maximal CETP activity (Biochim Biophys Acta 1996)
- Adding CETP to apoA-I transgenic mice doubles prebeta-HDL apoA-I and raises cholesterol efflux and LCAT esterification 1.7-fold (J Lipid Res 1996)
- Endotoxin cuts CETP levels below 20 percent of normal in hamsters, partly via TNF and interleukin-1 (J Clin Invest 1996)
- Combined hyperlipidaemia blocks net CETP-mediated cholesteryl ester transfer from HDL to LDL despite elevated CETP mass (Eur J Clin Invest 1996)
- N-linked glycosylation, not the N-terminal cysteine, proves essential for CETP lipid-transfer activity in a new Pichia pastoris recombinant expression system (J Lipid Res 1996)
- Analbuminemic patients show elevated CETP activity toward LDL, likely driven by lipoprotein-bound free fatty acids (Arterioscler Thromb Vasc Biol 1996)
- CETP activity, not mass, is elevated in Type 2 diabetes and tracks free cholesterol and apoA-I only in non-diabetic subjects (Atherosclerosis 1996)
- HDL particles from CETP-transgenic mice are more efficient cholesterol acceptors than from apoA-I-only transgenic mice, despite lower HDL levels (J Clin Invest 1995)
- CETP-mediated cholesteryl ester and triglyceride transfer in plasma is not an equimolar exchange (J Lipid Res 1995)
- Two novel compounds inhibit CETP by distinct mechanisms: U-95,594 competitively blocks all lipid transfer, U-617 selectively and irreversibly blocks CE transfer (Biochemistry 1995)
- CETP shuttles oxidized cholesteryl linoleate between LDL and HDL without distinguishing it from the unoxidized form (J Lipid Res 1995)
- The ratio of CETP mass to HDL3 cholesterol predicts carotid wall thickness better than HDL cholesterol itself (J Mol Med 1995)
- CETP co-expression halves HDL cholesterol and roughly doubles VLDL cholesterol in mice modeling type III hyperlipoproteinemia (J Biol Chem 1994)
- A monoclonal antibody against CETP raises hamster HDL cholesterol 33% and cuts HDL triglyceride 42% in vivo (Atherosclerosis 1994)
- PTP boosts the cholesteryl ester transfer activity of CETP even though the two proteins move phospholipids by distinct mechanisms (J Lipid Res 1994)
- Nine to twelve months of exercise training lowers plasma CETP concentration by about 14 percent (Arterioscler Thromb 1993)
- ApoE boosts CETP-mediated lipid exchange by raising the affinity of VLDL for CETP (J Lipid Res 1993)
- CETP generates pre-beta HDL-like particles from alpha HDL, completing a cyclical model with LCAT (J Lipid Res 1992)
- CETP drives HDL apolipoproteins A-I and A-II onto LDL particles, an effect greatly amplified by oleic acid (Biochim Biophys Acta 1992)
- Primate CETP transgene dose-dependently depletes large HDL1/HDL2 particles in mice, correlating -0.81 with plasma apoA-I levels (Arterioscler Thromb 1992)
- Alcohol abusers have 27 percent lower plasma CETP concentration and 22 percent lower CETP activity than controls (J Lipid Res 1992)
- The human CETP gene transcript is alternatively spliced to skip exon 9, producing an inactive, poorly secreted protein variant (Biochemistry 1992)
- CETP and hepatic lipase together shed apoA-I from HDL, which reassembles into new discoidal particles (Biochim Biophys Acta 1992)
- ApoA-II blocks CETP-driven conversion of reconstituted HDL into small particles, while apoA-I-only HDL splits into both large and small particles (J Lipid Res 1992)
- Hepatic sinusoidal cells, not hepatocytes, are the principal source of CETP mRNA in primate liver (J Biol Chem 1991)
- Medium-chain saturated fatty acids boost CETP-driven formation of very small HDL particles, while arachidonic acid blocks it (Biochim Biophys Acta 1991)
- CETP-mediated cholesteryl ester transfer rises with acyl chain length while selective cellular uptake falls, an inverse relationship across four cell types (J Lipid Res 1991)
- Cloning cynomolgus monkey CETP reveals hepatic mRNA rises fourfold with diet and correlates inversely with HDL cholesterol (ATVB 1991)
- CETP activity falls 15 percent in hypothyroidism, tracking changes in HDL lipid composition (Eur J Clin Invest 1990)
- Alcoholics have 28 percent lower CETP activity than controls, explaining their elevated HDL cholesterol (Eur J Clin Invest 1990)
- CETP is identical to the mysterious HDL conversion factor, and fatty acids greatly amplify its particle-shrinking effect (Biochim Biophys Acta 1990)
- HDL triglyceride and free cholesterol content noncompetitively inhibit CETP, while HDL apoprotein composition uncompetitively modulates it (J Lipid Res 1989)
- A neutralizing monoclonal antibody doubles HDL cholesteryl ester in rabbits by blocking CETP in vivo (J Clin Invest 1989)
- CETP boosts Hep G2 cell uptake of HDL cholesteryl esters indirectly, via LDL receptor-mediated re-uptake of secreted lipoproteins, not directly (J Biol Chem 1989)
- Dalcetrapib reduces red blood cell sickling in sickle cell disease and boosts the effect of voxelotor when combined (Clin Hemorheol Microcirc 2026)
- A review traces how CETP-inhibitor design evolved from first-generation scaffolds plagued by off-target toxicity to optimized late-generation clinical candidates (Eur J Med Chem 2026)
- Review weighs CETP-expressing hamsters against mice and rats for translational relevance in atherosclerosis modeling (Int J Mol Sci 2025)
- Proteomics plus Mendelian randomisation could have flagged the blood-pressure toxicity of torcetrapib before ILLUMINATE, a proof-of-concept analysis argues (medRxiv preprint 2025)
- Mouse mechanism study: CETP inhibition raises HDL, which blocks IL-1beta activation via SR-B1 and cuts endotoxaemia mortality (J Lipid Res 2025)
- CETP expression raises body metabolism and leanness in female mice during both cold exposure and thermoneutrality (FASEB J 2025)
- Evacetrapib more than doubled circulating ApoA5 in the ACCELERATE and ACCENTUATE trials, explaining how CETP inhibitors lower triglycerides (J Clin Lipidol 2025)
- CETP expression rises with obstructive sleep apnoea severity in obese young rats (Sleep Breath 2024)
- Correcting hyperglycemia does not restore apoC1 inhibition of CETP activity in type 1 diabetes (Metabolites 2024)
- CETP gene polymorphisms are linked to blunted heart rate response to exercise, first study of its kind reports (Int J Mol Sci 2024)
- CETP damages perivascular fat function in male mice through oxidative stress and inflammation, but preserves it in females (Function (Oxf) 2024)
- Anacetrapib reduces mortality from pneumococcal sepsis in mice by priming monocytes and speeding bacterial clearance (JCI Insight 2024)
- Mendelian randomisation flags genetically proxied CETP inhibition as associated with higher male infertility risk, partly via vitamin D (Front Endocrinol 2024)
- CETP variants, an update: a review maps how CETP structure, animal models and SNPs shape lipid profiles and cardiovascular risk (Curr Pharm Des 2024)
- Review examines how CETP and peripheral lipoproteins may contribute to vascular cognitive impairment and dementia (Mol Neurodegener 2023)
- Combined GIPR/GLP1R agonism additively lowers triglycerides, hepatic steatosis and Kupffer-cell-driven liver inflammation in CETP-humanised NAFLD mice (EBioMedicine 2023)
- Time-restricted eating reduces atherosclerotic lesion size and inflammatory cell content in CETP-humanised mice during simulated shift-work (EBioMedicine 2023)
- CETP gene haplotypes raise cardiovascular risk partly through mechanisms independent of triglycerides and HDL cholesterol (Int J Mol Sci 2023)
- Adcy9 gene inactivation shrinks infarct size and preserves cardiac function after MI, but mainly when CETP is absent (Can J Cardiol 2023)
- CETP missense variants raise HDL cholesterol mainly by reducing protein secretion, not intrinsic lipid-transfer activity (PLoS One 2023)
- Mendelian randomisation finds genetically proxied CETP inhibitors protect against sepsis, an effect explained largely by ApoA-I (Front Cardiovasc Med 2023)
- Dalcetrapib and anacetrapib generate large apoE-containing HDL particles that can bind the hepatic LDL receptor (J Lipid Res 2023)
- CETP activity raises brain cholesterol levels by reducing cholesterol efflux in transgenic mice (J Lipid Res 2022)
- LDL particle size governs how the natural CETP inhibitor ApoF binds and activates in hyperlipidaemic plasma (J Lipid Res 2022)
- Unlike three other newly identified EGPA biomarkers, CETP is selectively downregulated and negatively correlates with eosinophil count, aiding diagnosis versus severe asthma (Front Immunol 2022)
- A novel hypothesis links high East Asian CETP deficiency prevalence to historical resistance against a liver-damaging parasite (Front Cell Dev Biol 2022)
- Long-term matcha green tea worsens reverse cholesterol transport and fails to prevent diet-induced arteriosclerosis in rabbits (Mol Nutr Food Res 2021)
- Elafibranor reduces steatosis, hepatic inflammation and fibrosis progression in CETP-humanised NASH mice, with 87% pathway overlap to human NASH (Sci Rep 2021)
- The low-density lipoprotein receptor is required for CETP to control triglyceride metabolism in mice of both sexes (Physiol Rep 2021)
- Human ApoC1 transgene reduces atherosclerosis in rabbits partly by inhibiting CETP activity (Atherosclerosis 2021)
- CETP inside endothelial cells directly causes oxidative stress and vascular dysfunction, independent of its effect on HDL (Biomolecules 2021)
- Sepsis rapidly suppresses LCAT and CETP activity while raising PLTP and endothelial lipase, with LCAT activity predicting mortality (Front Cell Dev Biol 2021)
- Desmodium gyrans extract raises HDL-promoting SR-B1 and apoA-I while lowering CETP expression in liver cells (Indian J Pharmacol 2021)
- Anacetrapib raises macrophage cholesterol efflux capacity in men, with the effect modified by haptoglobin genotype in diabetes (JAHA 2020)
- CETP shifts HDL toward small, immature particles in coronary heart disease patients (Clin Lab 2020)
- CETP impairs triglyceride clearance in male mice through androgen receptor signalling (Lipids 2020)
- An undesirable postprandial triglyceride response enhances CETP-mediated cholesteryl ester transfer to chylomicrons and reduces hepatic HDL cholesteryl ester uptake (Biomolecules 2020)
- Exon-9-deleted CETP isoform blocks full-length CETP secretion and redirects cells toward storing triglyceride (J Lipid Res 2020)
- Homozygous B4GALT1 mutations cause CETP hypoglycosylation and reduced activity, yielding larger HDL particles (J Inherit Metab Dis 2020)
- Liposomal CETP vaccine protects rabbits against atherosclerosis where the failed clinical peptide vaccine did not (Pharm Dev Technol 2019)
- An anacetrapib analog cuts CETP activity by 89% and reduces neointimal hyperplasia in bypassed rabbit veins by 38% (Sci Rep 2019)
- Alternating light-dark cycles mimicking shift work roughly double atherosclerotic lesion size and severity in CETP-humanised mice (J Pineal Res 2019)
- CETP redirects cholesterol elimination away from the gut and toward bile, steering HDL cholesteryl esters differently than those from LDL (Arterioscler Thromb Vasc Biol 2019)
- Four weeks of oral Akkermansia muciniphila lowers cholesterol and reshapes immune cell populations in CETP-humanised mice, but does not reduce cuff-induced neointima formation (Mol Nutr Food Res 2019)
- Neither a liraglutide RCT nor a 1,611-person cohort finds any link between liver fat content and circulating CETP, despite CETP's hepatic Kupffer-cell origin (Sci Rep 2019)
- Genetic CETP deficiency loads HDL with apoE, apoC-III, ANGPTL3 and complement proteins, offering a clue why high HDL-C doesn't protect these patients (J Clin Lipidol 2019)
- Lower CETP levels track with more severe heart failure and higher natriuretic peptide (Lipids Health Dis 2018)
- ADCY9 inactivation cuts atherosclerosis by 65 percent in mice, but only when CETP is absent (Circulation 2018)
- Review contrasts disappointing CETP antagonists with the anti-inflammatory promise of the CETP agonist probucol (Atherosclerosis 2018)
- Metabolic liver inflammation in obesity does not clearly lower CETP, unlike bacterial-endotoxin activation of Kupffer cells (Atherosclerosis 2018)
- Diet-induced weight loss fails to improve HDL cholesterol efflux or cholesteryl ester transfer in obese men (Atherosclerosis 2018)
- Bacterial LPS lowers CETP by switching off resting Kupffer cells, an anti-inflammatory response that raises HDL during infection (J Am Heart Assoc 2018)
- CETP and its inhibitors, a foundational review: structure, mechanism, non-lipid functions and the full outcomes-trial record for four small-molecule inhibitors (J Lipid Res 2018)
- Aerobic exercise reshapes arterial and macrophage gene expression toward atheroprotection in CETP-transgenic mice, independent of changes in CETP activity (Front Physiol 2018)
- Statin-driven normalisation of HDL lipid composition lags behind LDL and apoB reduction, revealing role of CETP (J Clin Lipidol 2018)
- Inhibiting CETP with des-fluoro-anacetrapib cuts in-stent intimal area by 43% via a scavenger receptor-B1-dependent pathway (ATVB 2017)
- Electron microscopy shows torcetrapib and anacetrapib block CETP by favoring binary complexes over ternary lipoprotein bridging (Biochim Biophys Acta 2017)
- Molecular dynamics simulations show torcetrapib, anacetrapib, and evacetrapib all destabilize the hydrophobic tunnel of CETP (J Biomol Struct Dyn 2018)
- CETP knockout rabbits show less atherosclerosis, better cholesterol efflux, and HDL that suppresses endothelial adhesion molecules (Arterioscler Thromb Vasc Biol 2017)
- Anacetrapib lowers VLDL triglyceride only on a statin background, by boosting the catabolic rate of VLDL-TG (J Lipid Res 2017)
- CETP activity is highest in cord and maternal blood of growth-restricted neonates, alongside multiple proatherogenic lipoprotein changes (J Clin Lipidol 2017)
- Pigs bred for high CETP activity show altered hepatic expression of inflammatory genes and microRNAs, with gender and breed effects (Mamm Genome 2016)
- Structural study refutes the ternary tunnel complex model of how CETP transfers cholesteryl ester (J Struct Biol 2016)
- Across 6,606 adults and multiple imaging-based fat measures, no association is found between body fat and serum CETP, challenging the adipose-tissue-as-CETP-source hypothesis (Atherosclerosis 2016)
- CETP expression does not alter glucose tolerance, insulin secretion, or tissue glucose uptake in transgenic mice across multiple conditions (Lipids Health Dis 2016)
- Plasma CETP causes pancreatic beta cell dysfunction via islet cholesterol accumulation in mice (Nutr Metab 2016)
- White adipose tissue accumulates anacetrapib up to 40-fold, explaining its long elimination half-life in mice (Drug Metab Dispos 2016)
- A new non-steady-state tracer method shows anacetrapib blocks 97% of postprandial triglyceride flux into HDL (J Lipid Res 2016)
- Contrary to expectation, higher plasma TMAO from L-carnitine correlates with smaller aortic lesions in CETP-expressing ApoE-deficient mice (Atherosclerosis 2015)
- Anacetrapib lowers VLDL/LDL cholesterol through both CETP inhibition and a separate PCSK9-lowering mechanism in mice (J Lipid Res 2015)
- Two linked upstream CETP variants have opposite effects on gene expression via disrupted transcription factor binding sites (Pharmacogenet Genomics 2015)
- CETP-deficient cells cannot efficiently convert diglyceride into stored triglyceride (J Lipid Res 2015)
- Inhibiting CETP with des-fluoro-anacetrapib doubles capillary density in ischemic rabbit hindlimbs via SR-B1 and PI3K/Akt signaling (Int J Cardiol 2015)
- In vivo, anacetrapib promotes rather than blocks cholesteryl ester flux into large HDL, contradicting in vitro homotypic-transfer predictions (Eur J Pharmacol 2015)
- Inhibiting CETP with des-fluoro-anacetrapib nearly doubles re-endothelialization after balloon injury in rabbit aortas (ATVB 2015)
- Overexpressing full-length CETP in fat cells cuts triglyceride accumulation in half by boosting turnover and blocking synthesis (J Lipid Res 2015)
- Atomistic simulations show anacetrapib lodges in the N-terminal tunnel of CETP to block cholesteryl ester diffusion (PLoS Comput Biol 2014)
- Cholesteryl ester diffusion and self-association within the HDL phospholipid bilayer set the pace of CETP-mediated lipid transfer (Arch Biochem Biophys 2014)
- Anacetrapib reshapes LDL particle subfractions differently than atorvastatin, and neither drug reduces the smallest LDL particles (J Clin Lipidol 2015)
- Dalcetrapib raises plasma campesterol only in patients with intact ABCA1 and ApoA1, a crossover trial finds (Lipids 2014)
- At matched CETP inhibition, only anacetrapib boosts macrophage-to-feces cholesterol excretion in dyslipidemic hamsters (Eur J Pharmacol 2014)
- CETP inhibitors reduce hepatic LDL receptor and PCSK9 via an off-target SREBP2 mechanism (Atherosclerosis 2014)
- In rhesus macaques, anacetrapib reproduces the human lipid response and significantly lowers plasma PCSK9 (Eur J Pharmacol 2014)
- HDL from patients with CETP- or hepatic-lipase-deficiency hyperalphalipoproteinemia is not dysfunctional and shows enhanced cholesterol efflux from macrophages (Atherosclerosis 2014)
- Glycation destroys apolipoprotein C1's natural ability to inhibit CETP in patients with diabetes (Diabetes Care 2014)
- Very low plasma CETP is linked to impaired HDL cholesterol efflux in the LURIC cohort (Eur J Clin Invest 2014)
- A single CETP gene variant, rs5883, is identified as the main driver of the exon-9-skipping splice form (Biochem Biophys Res Commun 2014)
- Review asks whether anacetrapib and evacetrapib can succeed where torcetrapib and dalcetrapib failed to reduce cardiovascular risk (Annu Rev Med 2014)
- Perspective argues HDL functionality, not HDL-C concentration, should guide the future evaluation of CETP inhibitors (Clin Pharmacokinet 2013)
- In hamsters, anacetrapib raises preβ HDL and reverse cholesterol transport without affecting cholesterol absorption, unlike dalcetrapib (J Lipid Res 2013)
- Antisense CETP inhibition, unlike anacetrapib, boosts macrophage reverse cholesterol transport in CETP-transgenic mice (J Lipid Res 2013)
- Schaefer argues CETP inhibitors fail to cut coronary risk because they disrupt normal HDL metabolism (Curr Opin Lipidol 2013)
- HDL3 reduces macrophage ER stress and partially restores apoE and CETP secretion suppressed by tunicamycin (Biochem Biophys Res Commun 2013)
- Endogenous CETP activity above 34% marks high cardiovascular risk in a cohort of 1,403 patients (Atherosclerosis 2013)
- CETP transgene protects obese female mice from insulin resistance via bile acid signalling (Mol Metab 2013)
- Network pharmacology points to PDGFR, HGFR, and IL-2 receptor as possible off-target drivers of the cardiovascular harm from torcetrapib (BMC Syst Biol 2012)
- Molecular dynamics simulation reveals CETP forms a more flexible structure in solution than in the crystal, supporting a continuous internal tunnel (Proteins 2012)
- CETP inhibition alone fails to boost reverse cholesterol transport in hamsters unless paired with the LDL-lowering drug berberine (Arterioscler Thromb Vasc Biol 2013)
- Crystal structures show torcetrapib and a second inhibitor block the lipid-transfer tunnel of CETP at its narrow neck (J Biol Chem 2012)
- Higher endogenous CETP activity boosts cholesterol efflux capacity via pre-beta1-HDL in women (Arterioscler Thromb Vasc Biol 2012)
- ApoC1's natural inhibition of plasma CETP is blunted in dyslipidaemic coronary artery disease patients (J Lipid Res 2012)
- Torcetrapib cuts apoB-48 production by nearly half, but the effect vanishes in patients already on atorvastatin (J Lipid Res 2012)
- Knocking down hepatic SR-BI raises CETP-mediated cholesteryl ester transfer from HDL to apoB lipoproteins and halves atherosclerotic lesion area in rabbits (Atherosclerosis 2012)
- CETP inhibition boosts the cholesterol-removing power of large HDL2b particles after a meal, but not their delivery to the liver (Atherosclerosis 2012)
- Hop-derived xanthohumol prevents atherosclerosis in CETP-transgenic mice by inhibiting CETP and enriching HDL with apoE (PLoS One 2012)
- Women with angina pectoris show enhanced CETP activity in both HDL and LDL alongside impaired HDL antioxidant enzymes (Int J Mol Med 2011)
- Anacetrapib shrinks medium and small LDL while paradoxically raising the smallest, densest LDL4b subfraction (J Lipid Res 2012)
- Torcetrapib boosts reverse cholesterol transport by 118 percent in obese, insulin-resistant transgenic mice (Clin Transl Sci 2011)
- ApoA-I stimulates CETP and apoE secretion from lipid-loaded macrophages via NF-kB inhibition and PKA activation (Biochem Biophys Res Commun 2011)
- A new reverse-phase-array lipoprotein-profiling method shows dalcetrapib, unlike torcetrapib and anacetrapib, spares pre-beta HDL formation (J Lipid Res 2011)
- Chemical remodeling of LDL, not release from its inactive complex, drives LTIP activation, requiring either LCAT or CETP activity (J Lipid Res 2011)
- Unlike torcetrapib, dalcetrapib shifts cholesterol homeostasis toward absorption markers rather than synthesis markers (Atherosclerosis 2011)
- Anacetrapib inhibited CETP 94% and boosted macrophage-to-feces cholesterol excretion in hamsters (J Lipid Res 2011)
- PPAR-delta agonist GW501516 lowers CETP activity alongside broad apoB and apoC-III kinetic changes in obese dyslipidemic men (J Clin Endocrinol Metab 2011)
- CETP actually boosts the ability of HDL to block LDL oxidation, a finding that may help explain why torcetrapib failed to slow vascular disease (IUBMB Life 2011)
- Review distinguishes CETP inhibitors from the CETP modulator dalcetrapib by their opposite effects on HDL2-to-HDL3 transfer (Curr Opin Lipidol 2011)
- CETP enhances insulin-stimulated glucose uptake in human adipocyte cells (Life Sci 2011)
- Aerobic exercise boosts macrophage-to-feces reverse cholesterol transport in CETP-transgenic mice without changing CETP activity (Lipids 2011)
- Tree shrew CETP structure-function mapping identifies Asn110 as essential for secretion and residues 344/452 as essential for cholesteryl ester transfer (Lipids 2011)
- A four-week rimonabant intervention in CETP-humanised mice cuts body weight 9.4% and plasma cholesterol 24%, with systems-lipidomics revealing distinct plasma and liver lipid signatures (PLoS One 2011)
- CETP mutations raise HDL 27-hydroxycholesterol, and CETP mass correlates more strongly with 27OHC-ester than cholesteryl ester transfer (Atherosclerosis 2010)
- Naturally low CETP and PLTP activity may explain atherosclerosis resistance in tree shrews and Beijing ducks (Lipids Health Dis 2010)
- Up-titrated rosuvastatin and atorvastatin both significantly reduce CETP mass and activity in low-HDL-C cardiovascular patients (Curr Med Res Opin 2010)
- Postprandial lipemia boosts HDL2's cholesterol efflux capacity but raises CETP-mediated transfer and impairs hepatic HDL delivery in type IIB hyperlipidemia (J Lipid Res 2010)
- Review argues CETP may be atheroprotective and aid host defense, complicating the case for inhibiting it (Cardiovasc Ther 2011)
- Thirty-five days of bed rest raises plasma CETP by 27% independently of fat mass in healthy men (J Clin Endocrinol Metab 2010)
- A review explains why CETP-expressing hamsters, not mice, are the preferred preclinical model for testing reverse-cholesterol-transport drugs (Curr Opin Investig Drugs 2010)
- Davidson explains how triglycerides turn CETP into a generator of small, dense, atherogenic LDL and HDL particles (J Clin Lipidol 2010)
- Torcetrapib raises blood pressure in dogs through systemic and pulmonary vasoconstriction that also strains the heart (J Cardiovasc Pharmacol 2009)
- HDL from patients on high-dose torcetrapib removes more cholesterol from macrophages, correlating with the atheroma regression seen on the drug (Am J Cardiol 2009)
- Chapman and colleagues place CETP at the center of how statins, fibrates, niacin, and CETP inhibitors modulate HDL (Eur Heart J 2010)
- The novel SR-BI inhibitor ITX5061 raises HDL cholesterol by 20% in humans and reduces atherosclerosis in mice regardless of CETP expression (Arterioscler Thromb Vasc Biol 2009)
- Apolipoprotein CI regulates CETP activity in human plasma but not in rabbit plasma, a species-specific mechanism (J Lipid Res 2009)
- Genome-wide protein-ligand network analysis maps the off-target pathways behind the hypertensive side effect of torcetrapib (PLoS Comput Biol 2009)
- A mathematical model shows torcetrapib and JTT-705 inhibit CETP more potently than classic competitive inhibition would predict (J Lipid Res 2009)
- Torcetrapib raises apolipoprotein A-II levels by slowing its clearance and shifting it into a different HDL subpopulation (J Lipid Res 2009)
- A PADRE T-cell epitope CETP vaccine paired with CpG adjuvant elicits stronger anti-CETP antibody responses than the CETi-1 vaccine in mice and rabbits (Hum Vaccin 2009)
- CETP-mediated cholesterol transfer cannot substitute for SR-BI in adrenal steroid production (J Lipid Res 2009)
- Torcetrapib partly restores healthy HDL2 and HDL3 function in type IIB hyperlipidemia, boosting cholesterol efflux by up to 38 percent (Arterioscler Thromb Vasc Biol 2009)
- Diet-induced hypercholesterolemia raises plasma LTIP mass 2.5-fold while suppressing its hepatic mRNA, diverging from CETP's response in hamsters and rabbits (J Lipid Res 2008)
- Natural variation in plasma CETP levels does not affect RAAS responsiveness or blood pressure reactivity in healthy men (Expert Opin Ther Targets 2008)
- Only triglyceride-rich apoB lipoprotein subclasses accept cholesteryl esters transferred by CETP (Eur J Clin Invest 2008)
- Both wild-type CETP and its poorly secreted splice variants trigger the same endoplasmic reticulum stress response (J Lipid Res 2008)
- Torcetrapib produces smaller but more inflamed, less stable plaques than atorvastatin in humanized transgenic mice (Circulation 2008)
- Cyclosporine and Rapamycin, but not Tacrolimus or Mycophenolate, raise in vitro CETP activity while all four immunosuppressants suppress lipoprotein lipase (Int J Pharm 2008)
- Review questions whether CETP inhibitors remain a viable therapeutic approach after a major trial failure (Cardiovasc Ther 2008)
- CETP promoter variant linked to lower CETP levels also impairs the ability of plasma to remove cholesterol from cells, a possible clue to its cardiovascular risk (Biochim Biophys Acta 2008)
- Both raising and lowering CETP activity can enhance reverse cholesterol transport, depending on the species and pathway studied (Cardiovasc Res 2008)
- A review proposes that the now-known crystal structure of CETP could guide the design of inhibitors that avoid the nonproductive HDL complex formed by torcetrapib (Am J Cardiol 2007)
- Torcetrapib reduces VLDL apolipoprotein E levels alone, but on background atorvastatin instead boosts its content and speeds VLDL clearance (J Lipid Res 2008)
- Patients with the highest CETP-driven cholesteryl ester transfer rate had their first heart attack 18 years earlier (J Am Coll Cardiol 2007)
- Torcetrapib cuts postprandial VLDL-1 by 40 percent and reduces its atherogenic cholesteryl-ester content in type IIB hyperlipidemia (Arterioscler Thromb Vasc Biol 2008)
- Three newly discovered rat gene loci determine whether human CETP causes severe hypercholesterolemia when expressed as a transgene (J Hypertens 2007)
- A review says the CETP crystal structure could enable inhibitors that avoid the nonproductive HDL-binding complex formed by torcetrapib (Curr Opin Cardiol 2007)
- CETP overexpression in transgenic mice does not impair macrophage reverse cholesterol transport or HDL's LDL-antioxidant activity (Atherosclerosis 2007)
- The first molecular characterization of avian CETP finds chicken CETP activity rises with dietary cholesterol and falls with egg-laying maturity, likely regulated by estrogen (Comp Biochem Physiol B 2007)
- Torcetrapib cuts aortic atherosclerosis by 60 percent in rabbits fed an atherogenic diet, tracking the ratio of total cholesterol to HDL (J Lipid Res 2007)
- Doubling the dose of torcetrapib from 60 to 120 mg turns a modest boost in macrophage cholesterol efflux into a dramatic one (Arterioscler Thromb Vasc Biol 2007)
- A critical appraisal argues high CETP may actually lower cardiovascular risk when triglycerides are low, complicating the case for CETP inhibition (Eur J Clin Invest 2007)
- Plasma CETP activity tracks hepatic cholesterol synthesis machinery in humanized transgenic mice (Clin Exp Pharmacol Physiol 2006)
- Chimeric fusions of CETP with the bacterial-binding protein BPI retain function from both parent proteins up to a threshold (Biochemistry 2006)
- CETP expression amplifies hepatic cholesteryl ester and triglyceride accumulation from apoC-I deficiency by up to 302% in mice (J Lipid Res 2007)
- Partial, not complete, CETP inhibition preferentially blocks lipid transfer to LDL while sparing HDL flux (Atherosclerosis 2006)
- Torcetrapib raises large alpha-1 HDL particles by more than 50 percent in humans, mainly by slowing ApoA-I breakdown (Curr Opin Lipidol 2006)
- CETP expression speeds hepatic uptake of HDL cholesteryl ester but leaves VLDL secretion and biliary cholesterol excretion unchanged in mice (Atherosclerosis 2007)
- CETP is shown to directly drive formation of cholesterol-rich remnant lipoprotein particles, and JTT-705 blocks the effect (Clin Chim Acta 2007)
- Torcetrapib alone clears apoB100 faster, but added to atorvastatin it instead cuts LDL and IDL production (Arterioscler Thromb Vasc Biol 2006)
- ApoE-containing HDL activates LCAT less efficiently than apoA-I-HDL and is remodeled by CETP into large fusion products instead of small lipid-poor particles (J Lipid Res 2006)
- Human apoA-I overexpression strips apoC-I from HDL and removes most of HDL's natural CETP-inhibitory capacity in transgenic rats (J Lipid Res 2005)
- Two novel CETP gene variants are found in humans, and torcetrapib inhibits both variant and normal CETP equally (Biochim Biophys Acta 2005)
- CETP directly delivers HDL cholesteryl ester to the liver through a receptor-independent pathway that torcetrapib only partly blocks (Arterioscler Thromb Vasc Biol 2005)
- REGRESS Study identifies three interacting CETP promoter variants that jointly determine plasma CETP concentration (Hum Mol Genet 2005)
- JTT-705 blocks vascular smooth muscle cell proliferation and angiogenesis through a mechanism independent of CETP inhibition (Atherosclerosis 2005)
- Torcetrapib raises apolipoprotein A-I in alpha1-migrating HDL by up to 382 percent at twice-daily dosing, without changing fecal sterol excretion (Arterioscler Thromb Vasc Biol 2005)
- Torcetrapib inhibits every common CETP genetic variant equally, even the two that are naturally more stable in the body (J Biol Chem 2005)
- SR-BI corrects the atherogenic, cholesteryl-ester-rich HDL seen in CETP deficiency (Atherosclerosis 2004)
- Review catalogs ten CETP mutations behind hyperalphalipoproteinemia in Japanese CETP-deficient subjects (J Atheroscler Thromb 2004)
- Oleate-induced negative surface charge on LDL blocks LTIP activity at ten micromolar while only fully suppressing CETP above twenty micromolar (J Lipid Res 2003)
- Review names CETP-driven triglyceride enrichment of HDL as a key mechanism of low HDL in insulin resistance (Clin Biochem 2003)
- CETP expression completely abolishes LXR-agonist-induced HDL enlargement in mice (J Biol Chem 2003)
- Intravenous apoA-I/phosphatidylcholine discs raise plasma CETP concentration by 29.7% and cholesterol esterification rate by 69.5% within 12 hours in healthy men (Arterioscler Thromb Vasc Biol 2003)
- Red pepper supplementation lowers CETP activity and improves the lipid profile in cholesterol-fed rabbits (Clin Chim Acta 2003)
- JTT-705 (dalcetrapib) inhibits CETP and raises HDL-C across five animal species, mimicking CETP-deficient humans in marmosets (Eur J Pharmacol 2003)
- A newly discovered CETP splice variant in rabbit intestine, and its human counterpart, lacks the lipid-transfer-critical carboxy-end (Mol Cell Biochem 2003)
- REGRESS study haplotype analysis shows -629C/A, not TaqIB, drives CETP concentration and HDL-C (Hum Mol Genet 2003)
- JTT-705 raises HDL cholesterol but fails to reduce aortic atherosclerosis in rabbits with severe hypercholesterolaemia (Clin Sci 2002)
- Bariatric-surgery weight loss of 28.7 kg lowers CETP mass 27% and activity 25% in morbidly obese women, alongside an increase in LDL particle size (Arterioscler Thromb Vasc Biol 2002)
- Chiral resolution of a trifluoro-3-amino-2-propanol lead reveals a 40-fold potency boost, reaching IC50 0.02 micromolar against CETP (J Med Chem 2002)
- ApoCI deficiency doubles CETP-driven HDL cholesteryl ester depletion in transgenic mice (J Biol Chem 2002)
- Adding CETP shifts lipoproteins toward VLDL and IDL/LDL, and appears to blunt diabetes-driven hyperlipidemia in LPL-deficient mice (J Lipid Res 2002)
- CETP activity is an independent predictor of LDL particle size in familial combined hyperlipidemia, alongside triglycerides and hepatic lipase (J Lipid Res 2002)
- Review explains why hypothyroidism keeps HDL normal or high via thyroid-hormone-regulated CETP suppression (Thyroid 2002)
- Novel CETP promoter variant -971G/A found to be a non-functional marker linked to HDL-C via other polymorphisms (Atherosclerosis 2002)
- CETP activity runs 2-3 times higher in hyperlipoproteinemia patients, peaking in Type V dyslipidemia (Atherosclerosis 2001)
- A fructose-enriched diet raises plasma and adipose CETP in hamsters despite lowering, not raising, insulin levels (Life Sci 2001)
- CETP transgenic mice reproduce the human-like cholesterol response to dietary fat type, with MUFA and PUFA lowering plasma cholesterol (Br J Nutr 2001)
- Suppressing CETP synthesis in fat cells causes cholesteryl ester to pile up threefold by blocking its normal mobilization (J Biol Chem 2001)
- Polyunsaturated fatty acids arachidonic, eicosapentaenoic, and docosahexaenoic halve CETP mRNA expression in HepG2 liver cells (Lipids 2001)
- One week of a high-cholesterol diet paradoxically shrinks myocardial infarct size in CETP-transgenic mice (Coron Artery Dis 2001)
- Review details CETP's LBP-gene-family membership and the molecular basis of CETP-deficiency hyperalphalipoproteinemia (Biochim Biophys Acta 2000)
- CETP activity falls in both growth hormone deficiency and acromegaly, tracking with IGF-1 and adrenal status (Atherosclerosis 2000)
- Phospholipid depletion shrinks reconstituted HDL from 9.2 to 8.0 nm and slows early cholesteryl ester transfer via CETP (J Lipid Res 2000)
- Review makes CETP deficiency the central explanation for hyperalphalipoproteinemia and its paradoxical coronary risk (Atherosclerosis 2000)
- Insulin fails to activate the CETP gene promoter in transfected rat fibroblasts, despite a role for C/EBPalpha (Mol Cell Biochem 2000)
- Ten CETP polymorphisms mapped in 568 heart-attack patients reveal alcohol-dependent effects on HDL cholesterol (Genet Epidemiol 2000)
- Feeding, not fasting, raises liver CETP mRNA two-fold and plasma CETP activity 20% in human-CETP transgenic mice, independent of insulin or glucose (J Nutr Biochem 2000)
- New CETP/-629 promoter variant lowers CETP mass and raises HDL cholesterol via Sp1/Sp3 repression (ATVB 2000)
- Blocking CETP-mediated cholesteryl ester transfer with an antibody makes LDL more resistant to oxidative modification (J Lipid Res 2000)
- LDL acts as a secondary cholesteryl ester donor to chylomicrons via CETP during postprandial lipemia (Atherosclerosis 1999)
- A 24-hour intravenous fat load leaves CETP activity unchanged acutely but raises it a week later (J Lipid Res 1999)
- CETP genotype, not insulin sensitivity, predicts how PLTP activity falls during hyperinsulinemia in men (J Lipid Res 1999)
- A review finds increased plasma CETP is atheroprotective in transgenic mice even with low but functional HDL, against prior assumptions (Atherosclerosis 1999)
- Estrogen raises LDL cholesterol and atherosclerotic lesions in apoB100xCETP transgenic mice without altering CETP activity (Arterioscler Thromb Vasc Biol 1999)
- Human CETP transgene worsens atherosclerosis in apoE- and LDL-receptor-knockout mice, but effect flips with apoA-I overexpression (ATVB 1999)
- Dietary palmitic acid raises CETP activity and mass versus lauric and oleic acid diets, with opposite effects on PLTP (Atherosclerosis 1999)
- Radiolabeled HDL cholesteryl ester lingers longer in rat plasma and clears more slowly from perfused liver after ex vivo CETP treatment (Proc Soc Exp Biol Med 1999)
- SREBP-1 activates the CETP gene in transgenic mice but is not required for its cholesterol-driven up-regulation (J Biol Chem 1998)
- Smoking lowers CETP activity and worsens postprandial HDL loss in normolipidemic men (J Lipid Res 1998)
- Desialylation of lipoproteins boosts CETP-mediated cholesteryl ester transfer from HDL while impairing reverse cholesterol transport (Atherosclerosis 1998)
- CETP mRNA is 96% higher in the immature stromal-vascular fraction of human fat tissue than in mature adipocytes, unlike lipoprotein lipase or apoE (Biochim Biophys Acta 1998)
- Probucol sustains elevated prebeta1-HDL in hypercholesterolemic patients while a low-cholesterol diet lowers it, tracking CETP mass change (Atherosclerosis 1998)
- A 28-residue peptide from hog plasma, related to apoC-III, inhibits CETP and clears 75 percent of plasma activity within an hour in vivo (Biochim Biophys Acta 1998)
- Oleic acid roughly doubles full-length CETP transcription in Caco-2 intestinal cells without affecting exon-9-deleted splice variant (Mol Cell Biochem 1997)
- Acute hyperinsulinemia suppresses plasma CETP activity via a fall in free fatty acids, less so in NIDDM patients than healthy subjects (Metabolism 1997)
- LPL activity predicts HDL cholesterol only when CETP is present in mice, revealing a species-specific LPL-CETP interaction (J Lipid Res 1997)
- Chemically blocking a single CETP cysteine residue selectively shuts off triglyceride transfer while leaving cholesteryl ester transfer intact (Biochim Biophys Acta 1997)
- Interferon alpha treatment for hepatitis C lowers CETP activity and mass alongside lipoprotein lipase and hepatic lipase (Hepatology 1997)
- Review surveys the molecular genetics of CETP deficiency and its still-controversial link to atherosclerosis (Curr Opin Lipidol 1997)
- CETP gene locus heterogeneity explains why healthy men with low HDL cholesterol carry higher CETP concentrations (ATVB 1997)
- Cholesterol feeding raises rabbit CETP production 416% and plasma mass 230%, tracing CETP through fast and slow HDL-bound pools (Arterioscler Thromb Vasc Biol 1997)
- Transgenic mice map distinct CETP promoter regions controlling liver, intestine, and adrenal expression (J Biol Chem 1996)
- Lipopolysaccharides alter both HDL and LDL size and charge while blocking CETP activity, one of three distinct inhibitory mechanisms identified (Biochim Biophys Acta 1996)
- CETP and PLTP push HDL particle size in opposite directions, and alcohol withdrawal reveals the effect in patients (J Biol Chem 1996)
- Vitamin E blocks 85% of the HCSF-diet-induced rise in hamster adipose CETP release and 70% of the plasma CETP activity increase (Atherosclerosis 1996)
- CETP contains an essential free cysteine in a hydrophobic pocket, inactivated by thiol-modifying reagents at nanomolar concentrations (Biochem Biophys Res Commun 1996)
- SW872 liposarcoma cells offer a high-output model for studying cholesterol-driven CETP secretion (J Lipid Res 1996)
- ApoA-IV activates CETP lipid transfer as effectively as apoA-I, binding lipid emulsions with similar affinity (Biochim Biophys Acta 1996)
- CETP activity rises 20% postprandially in controls but falls in NIDDM patients, despite 35% higher fasting CETP activity in diabetics (Atherosclerosis 1996)
- Net cholesteryl ester transfer is elevated in hypertriglyceridemic hemodialysis patients, tracking triglyceride levels rather than renal status (Am J Nephrol 1996)
- A panel of 16 new antibodies maps four distinct CETP regions essential for cholesteryl ester transfer activity (J Lipid Res 1996)
- CETP mediates the transfer of esterified oxysterols between lipoproteins, limiting their uptake into cells (J Lipid Res 1996)
- Review weighs whether cholesterol redistribution by CETP is proatherogenic or a step in protective reverse cholesterol transport (Horm Res 1996)
- Plasma free fatty acids raise CETP mass and HDL-to-VLDL/LDL transfer but not LDL-to-HDL transfer, a directionally selective effect (Arterioscler Thromb Vasc Biol 1995)
- A fluorescence assay tracks CETP-mediated lipid transfer to equilibrium in under 30 minutes, supporting an adsorption-exchange-desorption-diffusion mechanism (Chem Phys Lipids 1995)
- Review questions whether CETP-mediated cholesterol transfer to apoB lipoproteins undermines the antiatherogenic label of reverse cholesterol transport (Atherosclerosis 1995)
- Oleic acid, unlike linoleic acid, blocks the cholesterol-induced rise in CETP activity in hamsters (Atherosclerosis 1995)
- Liver-specific CETP transgenic mice show 30-40% lower HDL cholesterol and loss of the apoE-rich HDL1 subclass (Biochim Biophys Acta 1995)
- Endotoxin suppresses CETP via adrenal corticosteroid release, raising HDL in transgenic mice (J Clin Invest 1995)
- CETP deficiency yields abnormally large, cholesterol-rich apoA-I lipoprotein particles that bind but internalize poorly (Eur J Biochem 1995)
- A review synthesizes transgenic-mouse evidence that CETP links plasma triglyceride metabolism to low HDL cholesterol levels (Trends Cardiovasc Med 1995)
- Molecular genetics reveals CETP as both anti-atherogenic in human deficiency and pro-atherogenic when overexpressed in mice (J Intern Med 1995)
- Unesterified cholesterol up to 17 mol% speeds CETP-mediated lipid exchange without increasing CETP binding to the donor emulsion (Biochem J 1994)
- ApoA-II shields HDL from CETP-driven shrinkage by inhibiting hepatic lipase in transgenic mice (J Clin Invest 1994)
- A review proposes CETP as the mechanistic switch converting protective HDL2 into atherogenic lipoproteins when triglyceride-rich particles accumulate (Atherosclerosis 1994)
- Antibody-mediated CETP inhibition raises HDL 30 to 40 percent and produces large apoE-rich HDL particles in hamsters, peaking at day 4 (J Lipid Res 1994)
- Dietary cholesterol raises plasma CETP activity in baboons regardless of dietary fat type (Metabolism 1994)
- CETP triggers dissociation of lipid-free apoA-I from HDL only when VLDL or LDL are also present (J Lipid Res 1994)
- ApoA-II binds CETP and shuts down its cholesteryl ester transfer activity while apoA-I and apoA-IV enhance it at low doses (J Lipid Res 1994)
- CETP activity is higher in IDDM patients with macroalbuminuria but does not correlate with HDL, HDL2, or HDL3 cholesterol (Diabetes Care 1994)
- A bicycle marathon cuts CETP mass 29 percent and activity 14 percent while raising HDL cholesterol (Metabolism 1994)
- ApoAII enrichment of HDL3 acts as an uncompetitive inhibitor of CETP-mediated cholesteryl ester transfer (J Biol Chem 1994)
- LpA-I, not LpA-I:A-II, shows an inverse relationship with plasma CETP mass within the HDL3 density region (J Lipid Res 1994)
- An alternatively spliced CETP variant lacking exon 9 sequences blocks secretion of full-length CETP by forming inactive heteromeric complexes (J Biol Chem 1993)
- Gemfibrozil raises HDL3 cholesterol 16% and CETP activity in NIDDM patients, alongside 14.7% and 18.8% rises in LPL and hepatic lipase (Atherosclerosis 1993)
- A natural CETP inhibitor in selectively bred high-HDL baboons is identified as an N-terminal apoC-I fragment that binds apoA-I (J Lipid Res 1993)
- CETP activity and mass rise in primary biliary cirrhosis, more so with hyperalphalipoproteinemia, correlating tightly with each other (r=0.90) (Hepatology 1993)
- Probucol raises plasma CETP 31% while paradoxically lowering adipose CETP mRNA, suggesting effects beyond local synthesis (J Lipid Res 1993)
- A monoclonal antibody that blocks CETP's triglyceride transfer but not cholesteryl-ester transfer suggests the two lipids use distinct binding sites (J Biochem 1992)
- CETP and lipoprotein lipase together, not separately, shrink HDL particles via free fatty acid synergy (Biochim Biophys Acta 1992)
- Trans-elaidic acid increases CETP-mediated cholesteryl ester transfer while cis-oleic acid inhibits it at high concentration (Biochim Biophys Acta 1992)
- Medium and long chain nonesterified fatty acids boost CETP-mediated cholesteryl ester transfer while short chains do not (Biochim Biophys Acta 1991)
- A monounsaturated-fat diet lowers CETP activity more than a polyunsaturated diet, paralleling LDL cholesterol reductions (Atherosclerosis 1991)
- CETP activity is 70% higher in smoking IDDM men than controls and 30% higher than nonsmoking IDDM men (Diabetes Care 1991)
- Copper-induced plasma oxidation frees CETP from HDL and shifts it onto LDL more sensitively than known oxidation markers (J Lipid Res 1991)
- Plasma CETP rises as an adaptive response to peripheral cholesterol flux and jumps further with probucol treatment (Clin Cardiol 1991)
- In CETP deficiency, LDL cholesteryl esters trace back to intracellular ACAT rather than CETP-mediated transfer from HDL (J Lipid Res 1991)
- Sodium oleate disrupts the CETP-mediated LDL-HDL equilibrium, driving cholesteryl esters into a shrunken, lipid-depleted HDL fraction (Atherosclerosis 1990)
- ApoE-rich HDL that accumulates in CETP deficiency binds the LDL receptor with far higher affinity than LDL itself (J Clin Invest 1990)
- CETP-driven lipid transfer from HDL enlarges LDL particles, a candidate mechanism for LDL subfraction polymorphism (J Lipid Res 1990)
- Hepatic lipase shrinks HDL particles only when VLDL and CETP are both present, and lipoprotein lipase blocks the effect (Atherosclerosis 1990)
- Plasma CETP levels vary nearly fourfold and correlate with apoA-I and apoE, with CETP concentrated in 129-154 kD HDL3/VHDL particles (J Clin Invest 1990)
- A neutralizing antibody's epitope maps to CETP's C-terminal lipid-binding region, revealing its inhibition mechanism (J Biol Chem 1989)
- Inhibiting CETP amplifies apoA-IV and apoE redistribution among lipoproteins during ex vivo plasma incubation (J Lipid Res 1989)
- HepG2 hepatocytes secrete CETP activity bound mainly to apoA-I and apoA-II, unlike plasma's strong apoA-I skew, alongside a distinct heat-labile lipid-transfer inhibitor tied to apoE particles (Atherosclerosis 1989)
- A newly purified phospholipid transfer protein, LTP-II, lacks CETP cross-reactivity but boosts CETP-mediated cholesteryl ester transfer (J Lipid Res 1988)
- Cloning rabbit CETP reveals 81% homology to the human protein and liver-dominant tissue expression across primates and rabbit (J Lipid Res 1988)
- CaCo-2 enterocytes secrete CETP (LTP-I) exclusively from their basolateral surface at twice the rate of HepG2 cells, and uniquely regulate secretion by fatty acid levels (J Biol Chem 1988)
- Liver Hep G2 cells secrete CETP, acquiring asparagine-linked sugar and sialic acid during processing (J Biol Chem 1987)
- CETP activity and cholesteryl ester transfer rise two- to fourfold in hypercholesterolemic and dysbetalipoproteinemic plasma (J Clin Invest 1987)
- HepG2 human liver cells synthesize and secrete a protein immunochemically identical to plasma LTP-I, identifying hepatocytes as a candidate source (Arteriosclerosis 1987)
- A turmeric compound, calebin A, binds CETP nearly as tightly as torcetrapib in a computational drug-discovery screen (Res Pharm Sci 2026)
- Hepatic overexpression of the hepatokine Tsukushi impairs HDL-mediated reverse cholesterol transport in hamsters without changing CETP activity (J Lipid Res 2026)
- Molecular dynamics show mixed cholesteryl-ester and triglyceride cargo twists CETP into strained, asymmetric conformations (Phys Chem Chem Phys 2026)
- Reduced CETP activity accompanies an atherogenic small dense LDL profile in long-standing type 1 diabetes (Front Endocrinol 2026)
- Phospholipid plugs inside two side pores of CETP accelerate triglyceride transfer through a newly described 'gliding' mechanism (Comput Struct Biotechnol J 2026)
- Higher CETP concentration is linked to coronary plaques in familial hypercholesterolemia, but not independently after adjustment (J Clin Lipidol 2026)
- The EUROASPIRE IV survey finds lower CETP activity in coronary patients with elevated triglycerides and residual apoB-driven risk (Clin Chim Acta 2026)
- Cross-trait GWAS links hearing loss to HDL and triglyceride genetics, flagging CETP as a candidate druggable target (Mol Genet Genomics 2025)
- Blood gene-expression signature of ITGB3, VEGFA and CETP tracks the extent of coronary artery stenosis, odds ratio 7.49 (Biochemistry (Mosc) 2025)
- In Tangier disease, CETP activity drives an LDL-triglyceride buildup on top of near-total HDL loss, a four-patient case series shows (J Clin Endocrinol Metab 2025)
- Endothelial dysfunction develops earlier in male than female CETP-humanised hyperlipidaemic mice, preceding atherosclerosis (Geroscience 2025)
- A hierarchical transformer model identifies an APOA4-CETP epistatic interaction underlying triglyceride to HDL cholesterol ratio (bioRxiv 2025)
- Beyond small-molecule inhibitors: a review surveys CETP-targeted immunotherapy and vaccines as an emerging route to raising HDL (Hum Vaccin Immunother 2025)
- Chlorinated diaryl sulfonamides identified as potent new CETP inhibitors reaching 100 percent inhibition (Curr Comput Aided Drug Des 2025)
- Tofacitinib raises CETP and atherogenic lipids in rheumatoid arthritis patients naive to prior biologic therapy (J Clin Lipidol 2025)
- Case report finds pemafibrate paradoxically lowers HDL cholesterol in a patient with CETP deficiency (J Clin Lipidol 2025)
- CETP-driven HDL lowering, unlike ApoE knockout, does not worsen muscle wasting in dysferlin-deficient mice (Lipids Health Dis 2024)
- Mendelian randomisation finds higher genetically predicted CETP, alongside HMGCR and PCSK9, associated with greater aortic aneurysm risk (Eur J Prev Cardiol 2024)
- Knocking down CETP shrinks triple-negative breast cancer xenografts by 86% and restores tamoxifen sensitivity in resistant cells (IUBMB Life 2024)
- Ginseng compound Ginsenoside Re protects rat hearts from hypertrophy partly by suppressing CETP, matching the classical inhibitor anacetrapib (Cureus 2024)
- CETP and apoA1 levels rise in blood during recovery from COVID-19, opposite to the acute-phase pattern (Sci Rep 2024)
- Novel trifluoromethyl benzamides identified as potent CETP inhibitors with sub-micromolar activity (Curr Comput Aided Drug Des 2024)
- CETP-expressing mice heal cutaneous leishmaniasis lesions faster, shifting macrophages toward a healing M2 phenotype (Front Immunol 2024)
- Bioinformatics and molecular docking identify the soy isoflavone genistein as binding CETP among three key HDL-raising natural-product targets (J Transl Med 2023)
- CETP is one of only three lipid-metabolism proteins strongly enriched in pre-beta-HDL, the small, highly active HDL subspecies (Basic Res Cardiol 2023)
- CETP is among seven cholesterol-handling genes up-regulated in peripheral blood of coronary artery disease patients (Curr Issues Mol Biol 2023)
- Molecular dynamics explains why the R201S and double I443W/V198W mutations cripple lipid transfer through CETP by warping its tunnel geometry (Biophys Chem 2023)
- Simulating CETP as it really is, not the crystallography mutant, finds a new lead compound that jams its tunnel shut (Int J Mol Sci 2023)
- Bound phospholipids bend cholesteryl esters into a transferable shape inside CETP, with the N-terminal lipid doing most of the work (J Chem Inf Model 2023)
- Review names CETP among four validated targets for novel lipid-lowering therapies to prevent cardiovascular disease (Nat Rev Cardiol 2023)
- How CETP moves cholesterol between lipoproteins: a structural review of the mechanism behind torcetrapib, anacetrapib and obicetrapib (Curr Atheroscler Rep 2023)
- Review proposes probucol as an alternative stroke-prevention therapy for patients at high haemorrhage risk (Brain Circ 2023)
- Review notes that impaired apoC1 inhibition of CETP in diabetes may explain elevated CETP activity in diabetic patients (Cardiovasc Diabetol 2022)
- miR-16 simultaneously suppresses CETP alongside five other atherosclerosis-related genes in liver cells without toxicity (Sci Rep 2022)
- Increased fecal fatty acid and bile acid excretion, not cholesterol absorption, explains triglyceride-response heterogeneity in CETP-humanised mice (Nutrients 2022)
- CETP-overexpressing mice develop worse psoriasis-like skin lesions with higher inflammatory cytokines than normal mice (Lipids Health Dis 2022)
- CETP gene promoter hypomethylation is associated with coronary artery disease risk in a Chinese Han cohort (Mol Biol Rep 2022)
- A mathematical model of triglyceride lipolysis explains why cholesterol acquisition by HDL is maximal at intermediate HDL concentrations (Metabolites 2022)
- In APOE3-Leiden.CETP mice with diet-induced NASH, the oxysterol Oxy210 reduces adipose tissue IL-6, MCP-1 and macrophage markers (Int J Mol Sci 2022)
- Walnut supplementation as a statin adjuvant lowers CETP activity and raises HDL cholesterol in hypertensive patients (Clin Exp Hypertens 2022)
- CETP levels track liver enzymes and metabolic markers in psoriasis patients on systemic therapy (Metabolites 2022)
- Bis(trifluoromethyl) benzylamino benzamides identified as potent new CETP inhibitor lead compounds (Med Chem 2022)
- EPA, but not DHA, significantly lowers CETP activity in a crossover trial of omega-3 fatty acid supplementation (J Clin Lipidol 2022)
- Evacetrapib suppresses colorectal cancer cell growth by blocking Wnt/beta-catenin signaling and activating JNK (Biol Pharm Bull 2022)
- Plasma CETP, alongside EPCR, is an independent MACE risk factor in older men with chronic coronary syndrome and improves on the Framingham score (Front Cardiovasc Med 2022)
- Human CETP transgene boosts macrophage reverse cholesterol transport in mice, but cannot rescue PLTP deficiency (J Physiol Biochem 2021)
- CETP TaqB1 polymorphism interacts with dietary insulin index to shape cardiovascular risk in type 2 diabetes (Sci Rep 2021)
- The same cysteine-binding chemistry that makes dalcetrapib a CETP inhibitor also lets it block the SARS-CoV-2 3CL protease (ACS Omega 2021)
- A high triglyceride to HDL cholesterol ratio predicts elevated CETP activity in children (Indian J Pediatr 2021)
- Dalcetrapib (JTT-705) blocks SARS-CoV-2 cell fusion by disrupting spike protein disulfide bonds (FASEB J 2021)
- Molecular dynamics simulations reveal how sugar chains on CETP shape its lipid-transfer tunnel (J Chem Inf Model 2021)
- CETP pathophysiology and inhibition, an update: the drug class biology, trial status and adverse effects surveyed before obicetrapib phase 3 (Drug Discov Today 2021)
- Low CETP activity late in pregnancy, in mother and placenta alike, is linked to giving birth to small-for-gestational-age infants (Sci Rep 2021)
- CETP is used to illustrate why Mendelian randomization of drug targets differs methodologically from randomization of biomarkers (Nat Rev Cardiol 2021)
- Trivalent implant vaccine targets PCSK9, ApoB, and CETP as "cholesterol checkpoint" proteins (Adv Ther (Weinh) 2021)
- CETP pushes macrophages toward the M2 phenotype and worsens elastase-induced emphysema in mice, an unexpected lung-disease link (Front Immunol 2021)
- Cyclic and bicyclic urea and sulfamide cores yield new CETP inhibitors effective in vivo (Bioorg Med Chem Lett 2020)
- A novel anti-adipogenic role for CETP: it boosts brown fat activity and lipolysis to reduce body fat, across three animal models (Metabolism 2021)
- Roux-en-Y gastric bypass lowers CETP activity alongside other markers of HDL function in severe obesity (Obes Surg 2020)
- A new ELISA for oxidized HDL finds the highest levels in patients with CETP-deficiency-related hyperalphalipoproteinemia, and lower levels with probucol treatment (J Atheroscler Thromb 2021)
- Swapping dietary palmitic acid for stearic acid raises CETP mass without changing its activity (Clin Nutr 2020)
- Apolipoprotein F emerges as a natural, LDL-selective inhibitor of CETP (Curr Opin Lipidol 2020)
- Diet-induced metabolic syndrome triggers 1396 differentially expressed adipose transcripts, revealing immune and remodeling gene signatures in CETP-humanised mice (Genomics 2020)
- Neither ad libitum nor time-restricted voluntary wheel running altered atherosclerotic lesion size in CETP-humanised mice or lipid profile in obese men (Obesity (Silver Spring) 2020)
- LDL receptor enables a CETP-independent route for macrophage cholesterol to reach faeces, mouse study finds (Circ Res 2020)
- Diet-controlled type 2 diabetes speeds catabolism of several HDL proteins, and CETP activity tracks inversely with plasma adiponectin (Biomolecules 2020)
- Carriers of the CETP Taq1B B2 allele only show worse cholesterol with a high-sucrose diet or physical inactivity, a gene-environment study finds (J Hum Nutr Diet 2020)
- Red yeast rice supplement linked to extreme HDL cholesterol via apparent CETP downregulation in a case report (Lab Med 2020)
- Ellagic acid from unripe Rubus coreanus extract lowers hepatic CETP and HMG-CoA activity while raising LCAT activity, reducing cholesterol in rats (Nutrients 2020)
- In hypertensive rats made to express human CETP, blood pressure rose and fatty liver accelerated, yet atherosclerosis did not (Hypertens Res 2020)
- LXR and PPAR-alpha agonists suppress ApoF, the natural CETP regulator, via a shared hormone response element (Biochim Biophys Acta Mol Cell Biol Lipids 2019)
- Hydrocarbon-stapled peptides jam the self-binding switch of CETP more than fivefold better, a new route to blocking the protein (J Mol Graph Model 2020)
- Steered molecular dynamics show torcetrapib and anacetrapib block CETP by physically plugging its lipid-transfer tunnel (Biochemistry 2019)
- Lead triphenylethanamine CETP inhibitor shows clean blood pressure profile and robust efficacy (ACS Med Chem Lett 2019)
- Cynanchum wilfordii extract lowers CETP alongside cholesterol and apoB in adults with high LDL cholesterol (Nutrients 2019)
- High-dose PFOA raises HDL cholesterol by suppressing cholesteryl ester transfer activity in mice (Toxicol Sci 2019)
- Kiwifruit raises adipose CETP gene expression but not serum CETP activity in hamsters (Avicenna J Phytomed 2019)
- Colorectal cancer patients have higher CETP activity and lower LCAT and PON-1 activity, with CETP mass an independent risk predictor (Clin Biochem 2019)
- High-dose dietary inulin shifts gut bacteria and raises short-chain fatty acids without reducing cholesterol or atherosclerosis in CETP-humanised mice (Sci Rep 2018)
- CETP promotes exchange of the inflammatory apolipoprotein serum amyloid A between lipoproteins (Arterioscler Thromb Vasc Biol 2018)
- Existing CETP inhibitors were designed against an unglycosylated crystal structure, but simulations show four sugar chains reshape the tunnel dynamics of the protein (Proteins 2018)
- The C-terminal bound phospholipid grips CETP more tightly than the N-terminal one, keeping it bent and ready to carry lipids (J Phys Chem B 2018)
- Curcumin does not significantly change serum CETP levels in metabolic syndrome, trial finds (Avicenna J Phytomed 2018)
- Prebeta-1 HDL, the particle CETP feeds on, is elevated across three dyslipidaemia phenotypes in 2,435 people (J Clin Lipidol 2018)
- Exercise raises HDL in CETP-transgenic mice by lowering CETP activity 19%, and an anabolic steroid specifically blunts that effect (Lipids 2017)
- N,N-substituted amine derivatives yield a sub-micromolar CETP inhibitor lead compound (Molecules 2017)
- Six-month high-fat feeding of CETP-humanised male mice reveals a biphasic lipid response with insulin resistance preceding dyslipidemia, mirroring human ageing (Physiol Rep 2017)
- Human CETP transgenic pigs created as a new model for dyslipidaemia and atherosclerosis research (Lipids Health Dis 2017)
- CETP can carry triglycerides too, not just cholesteryl esters, and simulations show why the slower TG transfer happens (Sci Rep 2017)
- Basal-bolus insulin lowers maternal triglycerides in gestational diabetes without changing CETP activity (J Obstet Gynaecol Res 2017)
- Policosanol supplementation reduced CETP activity by up to 32% and lowered blood pressure in healthy adults (Int J Mol Med 2017)
- Fluorinated benzamide CETP inhibitors reach sub-micromolar potency, with fluorine position dictating activity (Med Chem 2017)
- CETP-overexpressing transgenic rabbits show more macrophage foam cells despite unchanged lesion area (Mediators Inflamm 2017)
- Kinetic tracer studies reveal CETP inhibition raises apoA-I and lowers apoB by shifting catabolism rates of HDL and LDL in opposite directions (Curr Opin Lipidol 2016)
- MF59-adjuvanted CETP vaccine protects rabbits from atherosclerosis without a strong antibody or CETP-activity effect (Iran J Basic Med Sci 2016)
- CETP knockout sensitizes estrogen-receptor-positive breast cancer cells to cholesterol-depleting cytotoxic agents (Genes Cancer 2016)
- Circulating PCSK9 levels and CETP plasma activity are independently correlated in patients with metabolic disease (Cardiovasc Diabetol 2016)
- Optimised benzylaminopropanamide derivative HL16 emerges as a sub-micromolar CETP inhibitor active in hamsters (Bioorg Med Chem 2015)
- BMS-795311 matches torcetrapib for raising HDL in hamsters without raising blood pressure or aldosterone synthase (J Med Chem 2015)
- Policosanol-loaded reconstituted HDL inhibits CETP activity by up to 47 percent and promotes tissue regeneration (Rejuvenation Res 2015)
- CETP variant rs5882 determines whether plant sterol consumption lowers triglycerides, crossover trial finds (Appl Physiol Nutr Metab 2015)
- Novel CETP inhibitor K-312 lowers PCSK9 through a CETP-independent SREBP mechanism (Am J Physiol Endocrinol Metab 2015)
- A review proposes that HDL regulates the beta2-adrenergic receptor pathway through the same ADCY9 signaling axis linked to dalcetrapib response (Arch Med Res 2015)
- Modeling shows the short half-life of the CETP inhibitor RG7232 drives oscillating on/off effects on lipoprotein metabolism (CPT Pharmacometrics Syst Pharmacol 2015)
- Simvastatin blunts the boost that dalcetrapib gives to cholesterol efflux from macrophages in vitro (Cardiovasc Drugs Ther 2015)
- A review shows PON1 activation and its flux across HDL particle sizes during maturation are blocked by CETP and LCAT inhibitors (Clin Chim Acta 2015)
- Computational mapping of CETP missense mutations identifies cholesterol-binding regions relevant to drug design (Arch Biochem Biophys 2014)
- Amino-acid-modified fungal pigment derivatives yield micromolar, non-competitive CETP inhibitors (Nat Prod Res 2014)
- Anti-CETP vaccine reduces atherosclerosis and fatty liver disease in cholesterol-fed rabbits (PLoS One 2014)
- Perspective reviews the discovery and development of CETP inhibitors for reducing residual cardiovascular risk (J Med Chem 2014)
- CETP activity and mass are lower in rheumatoid arthritis patients taking glucocorticoids (J Rheumatol 2013)
- CETP gene promoter methylation correlates with LDL-C, HDL-C, and HDL particle size in familial hypercholesterolaemia patients (Atherosclerosis 2013)
- Low-normal thyroid function raises plasma cholesteryl ester transfer in type 2 diabetes (Atherosclerosis 2013)
- Specific lysophospholipid micelles reverse the beta-sheet, amyloid-fibril-forming conformation of a CETP C-terminus D470N mutant peptide back to alpha-helix (Biochem Biophys Res Commun 2013)
- Baseline plasma CETP activity is elevated in dyslipidaemic patients and correlates with triglycerides (Int J Clin Pharmacol Ther 2012)
- Tetrahydronaphthyridine CETP inhibitors reach nanomolar potency and raise HDL-C in transgenic mice (Bioorg Med Chem Lett 2012)
- Review by the developers of anacetrapib frames CETP inhibition as a new approach to cutting cardiovascular risk (Clin Pharmacol Ther 2012)
- Review explains why CETP inhibition raises HDL2 cholesterol without necessarily improving reverse cholesterol transport (Biochim Biophys Acta 2011)
- Leoligin, a lignan from Edelweiss, is identified as a novel CETP activator (Atherosclerosis 2011)
- Review surveys the controversial CETP-atherosclerosis relationship and emerging roles in Alzheimer's disease, inflammation and obesity (IUBMB Life 2011)
- CETP expression partly rescues abnormal HDL distribution but not atherosclerosis in SR-BI-deficient mice (J Biol Chem 2011)
- A disease-associated CETP mutation drives amyloid formation and cytotoxicity in vitro (Int J Mol Sci 2011)
- An orally delivered trefoil-factor-CETP chimeric vaccine raises intestinal and serum anti-CETP antibodies and inhibits atherosclerosis in rabbits (Peptides 2010)
- A structural-and-metabolic-network computational model predicts off-target causes of the hypertensive side effect of torcetrapib in kidney tissue (PLoS Comput Biol 2010)
- Two CETP inhibitors reach systemic circulation mainly via lymphatic transport, 22 to 28% of dose (Pharm Res 2010)
- A review of CETP molecular mechanisms notes the negative phase III torcetrapib trials challenged the future of the drug class (Cell Mol Life Sci 2010)
- CETP variant rs708272 improves diagnostic accuracy for identifying patients with active atherosclerosis (Swiss Med Wkly 2010)
- A review identifies CETP as a key enzyme liberating serum amyloid A during acute-phase HDL remodeling (Curr Opin Endocrinol Diabetes Obes 2010)
- A humanized transgenic mouse model shows torcetrapib raises HDL cholesterol by 53 percent, less than a potent PPAR-alpha agonist (J Cardiovasc Pharmacol Ther 2010)
- The rodent-specific scavenger receptor MARCO drives the off-target lipid uptake seen with dalcetrapib in mouse macrophages (Toxicol In Vitro 2010)
- A review argues that the harms of torcetrapib trace to its own tight CETP binding and an aldosterone-like effect, not to CETP inhibition itself (Rom J Intern Med 2010)
- CETP -629C>A promoter variant predicts HDL-C response to growth hormone only in glucocorticoid-treated patients (Eur J Endocrinol 2010)
- A review argues the mortality signal from torcetrapib traces to off-target toxicity, not to CETP inhibition itself (Am J Cardiol 2009)
- Review highlights a paradox, CETP protects against bacterial infection but promotes atherosclerosis (Atherosclerosis 2009)
- Statin-induced LDL and non-HDL cholesterol reductions track with falling CETP mass in type 2 diabetes (Expert Opin Ther Targets 2009)
- LCAT overexpression raises HDL cholesterol but does not boost macrophage reverse cholesterol transport, even alongside SR-BI or CETP coexpression (Circulation 2009)
- JTT-705, the dalcetrapib precursor compound, blocks LPS-triggered TNF-alpha production in mice by targeting a cysteine on MD-2 (J Biol Chem 2009)
- A conformationally constrained CETP inhibitor matches the HDL-raising efficacy of torcetrapib across hamsters, transgenic mice, and monkeys (J Med Chem 2009)
- Tetrahydroquinoline platform yields a 39nM CETP inhibitor for raising HDL-C (Bioorg Med Chem Lett 2009)
- A review links the B1B1 CETP genotype to higher CETP activity, lower HDL cholesterol, and more pronounced postprandial lipemia (Curr Med Chem 2009)
- CETP genetic variants are linked to plasma vitamin E levels, extending CETP genetics beyond cholesterol transport (Br J Nutr 2009)
- Biosensor mapping places the torcetrapib binding site at Cys-13 in the CETP lipid-binding pocket (Bioconjug Chem 2008)
- CETP variants shape cerebral and peripheral cholesterol metabolism but not Alzheimer's disease risk (Brain Res 2008)
- Review attributes statins' modest HDL-raising effect to reduced CETP-mediated cholesterol flow (Cardiovasc Drugs Ther 2008)
- A review argues ABCA1 and ABCG1 transporters, not raw HDL cholesterol level, drive HDL's atheroprotective effect after the torcetrapib failure (Cell Metab 2008)
- LTIP loses its CETP-inhibiting activity when sequestered into a 470 kDa apolipoprotein complex (J Lipid Res 2008)
- Probucol lowers ANGPTL3 and large-HDL phospholipids while raising prebeta1-HDL in hypercholesterolemic patients (Atherosclerosis 2008)
- ALPS study finds CETP mass changes track LDL cholesterol, not HDL, with the probucol derivative AGI-1067 (J Clin Lipidol 2007)
- Review dissects how CETP and PLTP jointly drive low HDL in type 2 diabetes via specific apolipoprotein modulators (Curr Opin Lipidol 2007)
- Review attributes chronic renal failure's HDL disorders partly to elevated CETP activity (Am J Physiol Renal Physiol 2006)
- Review dissects biochemical pathways beyond HDL-C by which CETP inhibition might protect against atherosclerosis (Arterioscler Thromb Vasc Biol 2006)
- Displaying CETP B cell epitopes on asparaginase induces high-titer anti-CETP antibodies lasting over eighteen weeks in mice (Protein Pept Lett 2006)
- ApoCI blocks CETP by disrupting CETP-HDL binding through its electrostatic C-terminal helix (J Biol Chem 2005)
- ABCG1's discovery as a large-HDL cholesterol exporter suggests CETP inhibition may enhance, not reduce, cholesterol efflux (Curr Opin Lipidol 2005)
- Review names CETP inhibition as an emerging strategy for HDL-targeted cardiovascular drug development (Nat Rev Drug Discov 2005)
- CETP transgenic rats show dramatic lipid shifts on a sucrose diet but not on a high-fat/high-cholesterol diet (Atherosclerosis 2005)
- Postprandial triglyceride-rich lipoproteins boost CETP-mediated cholesteryl ester transfer from LDL and HDL regardless of dietary fat type (Am J Clin Nutr 2004)
- A highly variable repeat in the CETP promoter forms unusual DNA structures and predicts HDL-C levels (Biochim Biophys Acta 2004)
- JTT-705 reshapes HDL toward larger, apolipoprotein E-rich particles with more antioxidant enzyme activity in rabbits (Arterioscler Thromb Vasc Biol 2004)
- Adjuvant-free Hsp65-CETP fusion vaccine induces antibodies lasting over 12 weeks and partially normalizes CETP activity in mice (Vaccine 2004)
- JTT-705 raises HDL cholesterol in rabbits by speeding up apolipoprotein A-I synthesis, not by slowing its breakdown (Atherosclerosis 2004)
- Mice and rats lack functional CETP due to a shared ancestral nonsense mutation, not altered regulation (Comp Biochem Physiol B 2003)
- Review proposes CETP has a novel biological function transporting water-insoluble drugs between lipoproteins (Biochem Pharmacol 2002)
- In type 1 diabetic children, arachidonic acid content of LDL cholesteryl ester correlates with CETP activity independent of CETP concentration, suggesting a route to excess LTB4 (Med Hypotheses 2002)
- Overexpressing phospholipid transfer protein raises VLDL secretion 1.5-fold while lowering HDL cholesterol and CETP activity in CETP-transgenic mice (J Lipid Res 2002)
- Atorvastatin cuts postprandial CETP-mediated cholesteryl ester transfer from HDL to chylomicrons by up to 26% (J Clin Endocrinol Metab 2002)
- Antioxidant vitamins blunt the protective HDL2 rise from simvastatin-niacin therapy, possibly by stimulating CETP activity, a review concludes (Arterioscler Thromb Vasc Biol 2002)
- A review reports that apolipoprotein A-II modulates HDL atherogenicity in opposing directions, inhibiting CETP activity as one of several intermediate effects on reverse cholesterol transport (Atherosclerosis 2002)
- HDL from rabbits treated with JTT-705 removes cholesterol from macrophages just as efficiently as normal HDL, despite higher CETP-inhibited levels (Atherosclerosis 2002)
- CETP inhibitory peptide P28 cuts CETP activity 50% and raises HDL/total-cholesterol ratio 150% in CETP-transgenic mice (J Biochem Mol Biol 2002)
- AICAR lowers blood glucose and insulin by suppressing endogenous glucose production, without correcting dyslipidaemia, in diabetic CETP-expressing KKAy mice (Diabetologia 2001)
- Lipid transfer inhibitor protein rises 3-fold in hypercholesterolemia independent of CETP levels themselves (Arterioscler Thromb Vasc Biol 2001)
- HDL cholesteryl esters still reach LDL in ponies despite their total lack of CETP activity (Comp Biochem Physiol B Biochem Mol Biol 2001)
- Early review surveys progress toward antisense and small-molecule CETP inhibitors as HDL-raising therapies (Curr Opin Drug Discov Devel 2001)
- Replacing a tetrafluoroethoxy group with 2-furyl heteroaryl moieties yields submicromolar CETP inhibitors in a new trifluoro-propanol series (Bioorg Med Chem Lett 2001)
- A review identifies apolipoprotein C-I as the major plasma inhibitor of CETP, one of several ways C-I and C-III modulate lipoprotein metabolism (Curr Opin Lipidol 2001)
- A dominant-negative CETP promoter mutation cuts transcriptional activity to 8% of wild type in Japanese hyperalphalipoproteinemia (ATVB 2001)
- A review finds PLTP, not CETP, is the main driver shaping HDL size and composition via phospholipid transfer and HDL conversion (Atherosclerosis 2001)
- Review traces how CETP deficiency reshapes HDL and LDL and raises coronary risk despite higher HDL-cholesterol (Front Biosci 2001)
- A chiral CETP inhibitor binds the protein 5,000-fold more efficiently than its natural lipid substrate (Biochemistry 2000)
- A review names CETP, apoA-II, and hepatic lipase as prime targets for pharmacologic inhibition among new HDL-directed atherosclerosis therapies (Curr Atheroscler Rep 2000)
- Hypertriglyceridemia with low HDL cholesterol raises CETP activity and impairs cellular cholesterol efflux capacity in men (Atherosclerosis 2000)
- Ferroverdin B, isolated from a soil Streptomyces, is among the most potent microbial CETP inhibitors known, with an IC50 of 0.62 micromolar (J Antibiot (Tokyo) 1999)
- C/EBP-beta binds the CETP gene promoter in liver cells but does not actually drive CETP expression (Atherosclerosis 1999)
- Insulin lowers CETP activity 9.5% in healthy adults but not in type 2 diabetes, while PLTP responds to both insulin and Acipimox in both groups (Diabetes 1999)
- A cholesterol response element in the CETP promoter explains why CETP rises, not falls, with cholesterol loading (J Lipid Res 1999)
- Fungal azaphilones inhibit CETP by forming a covalent bond with a lysine amine, with potency tracking ketone placement on the isochromane ring (J Antibiot (Tokyo) 1999)
- Testosterone suppression by cetrorelix raises apoA-I, insulin, and leptin, with only small CETP and hepatic lipase decreases in pooled analysis (Exp Clin Endocrinol Diabetes 1999)
- A review asks whether CETP is beneficial or harmful, weighing evidence for both proatherogenic and antiatherogenic roles (Crit Rev Clin Lab Sci 1998)
- High-viscosity pectin lowers plasma CETP activity along with cholesterol in hamsters (J Nutr 1998)
- Pravastatin lowers CETP activity in both fasting and postprandial states in hypercholesterolaemia (Atherosclerosis 1998)
- Smoking cuts lipoprotein lipase and LCAT activity but leaves CETP activity unchanged, though CETP still tracks HDL3 in non-smokers (Eur J Clin Invest 1998)
- CETP-driven cholesterol enrichment of remnant particles worsens atherosclerosis risk in diabetic dyslipidaemia (Eur Heart J 1998)
- An (i, i+4) residue array between His466 and Asp470 stabilizes an amphipathic alpha-helix in CETP's C-terminus (Biochim Biophys Acta 1998)
- Phage-display screening yields a pentapeptide, WRMWY, that competitively inhibits CETP (J Pept Res 1998)
- An overview of reverse cholesterol transport shows CETP pulling in the opposite direction from apoA-I (Eur Heart J 1998)
- PLTP shares the same optimal HDL surface charge as CETP, showing both lipid transfer proteins are governed by electrostatics (J Lipid Res 1998)
- HDL and VLDL levels, not CETP activity, determine the direction of cholesteryl ester transfer in alcohol abusers (Arterioscler Thromb Vasc Biol 1997)
- CETP shares seven lipid-binding helical arrays with apoA-I, apoA-II, apoC-I/II/III, and apoE despite a smaller active surface (Mol Cell Biochem 1997)
- Review contrasts how CETP and PLTP remodel HDL size distribution through distinct mechanisms (Trends Cardiovasc Med 1997)
- Intraperitoneal insulin normalizes elevated cholesteryl ester transfer in NIDDM, but injections alone do not (Diabetes 1997)
- Negatively charged surface lipids slow CETP-mediated cholesteryl ester transfer between microemulsion particles, positively charged lipids speed it up (Biochem J 1997)
- CETP activity, not LDL receptor pathways, may explain why LDL cholesterol rises with dietary fat in some people (Curr Opin Lipidol 1997)
- Antibodies raised against CETP residues 131-142 can immunoprecipitate CETP activity from serum without inhibiting the enzyme, marking a non-active-site epitope (Hybridoma 1996)
- A novel intron 10 splice mutation causes exon 10 skipping and disrupts downstream splicing in CETP deficiency (J Lipid Res 1996)
- Fenofibrate cuts CETP-driven cholesteryl ester transfer from HDL to VLDL by 38% and normalizes dense LDL (ATVB 1996)
- Net cholesteryl ester transfer roughly doubles in NIDDM even though CETP activity itself is unchanged (Atherosclerosis 1996)
- Free fatty acids fluidize the lipoprotein surface, offering a physical explanation for how they modulate CETP activity (Eur J Biochem 1996)
- CETP activity rises in the second trimester of pregnancy alongside falling hepatic lipase and rising estradiol (J Lipid Res 1996)
- Plasma triglycerides, not LCAT or CETP concentration, drive cholesterol esterification and HDL remodeling (ATVB 1995)
- A Tall-lab review reconciles CETP deficiency and CETP overexpression both showing antiatherogenic signals, via its role in reverse cholesterol transport (Curr Opin Lipidol 1995)
- Antibody-mediated CETP inhibition in hamsters produces apoE-rich, apoA-I-poor HDL particles that revert toward baseline within two weeks (Lipids 1995)
- Diabetic cynomolgus monkeys show accelerated cholesteryl ester transfer, mirroring human diabetic dyslipidaemia (J Lipid Res 1995)
- CETP shrinks reconstituted HDL from 9.2 to 8.0 nm by swapping cholesteryl ester for triglyceride and losing an apoA-I molecule (J Biol Chem 1995)
- CETP is localized to brain astrocytes, with increased expression in Alzheimer's disease gray matter (Acta Neuropathol 1995)
- Adding bezafibrate to long-term probucol therapy can trigger severe HDL and apolipoprotein A-I deficiency (Eur J Clin Pharmacol 1995)
- CETP transgenic mice develop more severe, faster-progressing fatty liver than controls, worse in males (Biochem Biophys Res Commun 1994)
- PD 140195, a triazole-thiol CETP inhibitor that mimics cholesteryl ester structurally, works noncompetitively and selectively blocks cholesteryl ester over triglyceride transfer (Lipids 1994)
- CETP and LCAT localize mainly to LpA-I, not LpA-I:A-II, particles, a review finds, explaining why LpA-I promotes more cholesterol efflux (Atherosclerosis 1994)
- Recombination experiments trace accelerated cholesteryl ester transfer in IDDM to a CETP-containing plasma fraction (Eur J Clin Invest 1994)
- CETP mRNA sequences are detected in ovary, lung, intestine, and heart tissue, not just liver, suggesting a locally active membrane-bound CETP form (Biochem Biophys Res Commun 1994)
- Enlarged HDL2 from CETP-deficient patients fails to protect macrophages from cholesterol accumulation (J Biochem 1994)
- Bezafibrate suppresses CETP activity by 17% and LCAT by 21% while shrinking small, heavy LDL (Atherosclerosis 1994)
- A review identifies probucol as the sole drug shown to stimulate CETP activity and boost reverse cholesterol transport (Pharmacol Ther 1994)
- Recombination experiments trace accelerated cholesteryl ester transfer in NIDDM to the VLDL plus LDL fraction (Atherosclerosis 1993)
- Heart transplant recipients' paradoxically high HDL traces to partial CETP and hepatic lipase deficiency (Atherosclerosis 1993)
- Review forecasts CETP activity as a promising future pharmaceutical target beyond conventional lipid-lowering (Circulation 1993)
- Simvastatin lowers cholesteryl ester transfer by reducing CETP concentration itself, not by altering HDL (Atherosclerosis 1993)
- CETP activity shows no relation to LDL subfraction composition, unlike lipoprotein and hepatic lipase (Atherosclerosis 1993)
- Heavy alcohol drinkers with sky-high HDL show sharply reduced CETP activity and mass, mimicking genetic deficiency (Metabolism 1992)
- CETP reshapes HDL3 differently depending on whether particles carry apoA-II alongside apoA-I (Biochim Biophys Acta 1992)
- A review by Alan Tall names CETP and hepatic lipase as key genetic determinants of HDL catabolism, with lipoprotein lipase driving HDL formation (J Intern Med 1992)
- CETP and PLTP occupy different HDL-sized macromolecular complexes across four vertebrate species (Atherosclerosis 1991)
- A review credits probucol as the only drug shown to directly raise CETP activity and mass, potentially aiding cholesterol removal from tissues (Atherosclerosis 1991)
- Doubling plasma CETP activity via diet does not speed cholesteryl ester clearance from hepatic reticuloendothelial cells in hamsters (Biochim Biophys Acta 1991)
- Impaired cholesteryl ester transfer to the HDL3 pool is linked to vascular disease across several hyperlipidemic disorders (Atherosclerosis 1989)
- A minor pre-beta lipoprotein containing apoD, LCAT, and CETP channels newly esterified cell cholesterol into HDL (J Biol Chem 1989)
- Radiation inactivation puts the functional size of CETP at 70 000 daltons, consistent with a monomer (FEBS Lett 1985)
- Stripping cholesteryl arachidonate from HDL via CETP-mediated transfer reduces its ability to trigger endothelial prostacyclin release (J Lipid Res 1985)
- Higher CETP activity predicts improved survival in sepsis-associated ARDS (bioRxiv 2026)
- N-alkylated benzazepine derivatives inhibit CETP with an IC50 of 75.54 ± 8.70 nM in a fluorescence assay (Bioorg Chem 2026)
- Tocilizumab decreases CETP activity by ~22% in 16 patients with rheumatoid arthritis (J Clin Lipidol 2026)
- CETP variants rs2033254 and rs12708980 associate with lower intestinal cholesterol absorption markers in a European GWAS (Nutrients 2026)
- CETP is over-expressed in non-small cell lung cancer and obicetrapib restores ferroptosis sensitivity in xenografts and organoids (Clin Transl Med 2026)
- A review positions CETP alongside PCSK9 and ANGPTL3 as emerging lipid-regulatory targets in cancer, though CETP-specific oncology research remains scarce (Biomolecules 2026)
- Preclinical safety battery clears the anti-CETP intranasal vaccine HB-ATV-8 for cardiac, mutagenic and metabolic risk (Arch Med Res 2026)
- In liver cells, miR-30b-3p cuts CETP reporter activity by 86% at the mRNA level, but CETP protein itself does not budge (Mol Biol Rep 2026)
- In CETP mice, obicetrapib plus ezetimibe on top of atorvastatin regresses established atherosclerosis by 44% via LDL-receptor-driven VLDL clearance (J Lipid Res 2026)
- Review surveys the evolving landscape of lipid-lowering drug targets, from statins to CETP and Lp(a) inhibition (Eur Heart J 2025)
- Machine learning and molecular dynamics show why obicetrapib binds the CETP hydrophobic tunnel more tightly than the failed torcetrapib (ChemMedChem 2025)
- Machine learning flags CETP as an immune biomarker for diabetes-tuberculosis comorbidity, AUC 0.804 (Microorganisms 2025)
- Chikungunya virus is sensitive to evacetrapib in cell culture, but through an off-target effect independent of CETP itself (Viruses 2025)
- Mendelian randomisation study finds no genetic link between CETP-mediated LDL-C and pulmonary vascular disease, unlike NPC1L1 and PCSK9 (Pulm Circ 2025)
- Repurposed as a cancer drug: evacetrapib blocks a CEA-KRT1 interaction that drives oxaliplatin resistance in gastric cancer (Drug Resist Updat 2025)
- Mendelian randomisation study centred on HMGCR also finds CETP-mediated LDL-C consistently associated with lower aortic aneurysm risk (Nutr Metab 2024)
- A review positions CETP alongside PCSK9 and CYP7A1 as the three central druggable regulators of cholesterol homeostasis (Life Sci 2024)
- A methodology review highlights the APOE*3-Leiden.CETP mouse as a model that closely mimics human lipoprotein metabolism (Vasc Biol 2024)
- First Mendelian randomisation of lipid drug targets and diabetic retinopathy finds a PCSK9 signal but no CETP association (J Lipids 2024)
- A four-protein urinary panel including CETP, combined with tumor diameter and AFP/GGT levels, predicts microvascular invasion in liver cancer with concordance indices up to 0.809 (BMC Med 2023)
- Systematic review of 49 cardiovascular calcification trials finds dalcetrapib among the singleton agents showing no benefit (J Am Heart Assoc 2023)
- A purple perilla extract lowers plasma CETP and reduces atheroma formation in apoE-deficient mice (Nutr Res Pract 2023)
- A probiotic strain lowers CETP expression alongside cholesterol-lowering effects in cell and animal models (J Med Food 2023)
- Cholesterol efflux capacity, but not CETP-mediated cholesterol ester transfer, correlates inversely with peripheral plaque volume (Biomedicines 2023)
- A probiotic normalises diet-induced CETP gene upregulation in a rabbit model of fatty liver disease (Sci Rep 2023)
- CETP is identified as a candidate serum biomarker for diagnosing sarcopenia in older adults (BMC Musculoskelet Disord 2022)
- CETP activity correlates with atherogenic VLDL levels in women with anorexia nervosa (Biomedicines 2022)
- Eating up to two eggs daily downregulates CETP mRNA in blood cells without affecting overall cholesterol balance in young Chinese adults (Food Sci Nutr 2022)
- Proteomic profiling flags CETP as one of three ELISA-confirmed markers elevated in stent restenosis (Front Cardiovasc Med 2022)
- HDL and CETP: a textbook chapter surveys the tunnel structure, reverse cholesterol transport role and the still-unsettled case for inhibitors versus agonists (Adv Exp Med Biol 2022)
- An ABCG1 gene variant is linked to higher CETP activity in a Brazilian population study (Biochem Genet 2022)
- Lower plasma CETP tracks with milder depression severity, including anhedonia and guilt, in a preliminary mood-disorder proteomics study (J Psychiatr Res 2021)
- A CETP isoform, CETPI, is highlighted as a newly described contributor to LPS inactivation in the gut-liver axis of sepsis (Biomed Pharmacother 2021)
- CETP concentration does not differ between peripheral artery disease patients with or without type 2 diabetes (Vasc Med 2021)
- Feed efficiency correlates with distinct hepatic gene-expression patterns across diet duration in CETP-humanised mice, per a new dynamic model (Physiol Rep 2021)
- Fetal HDL carries reduced CETP activity despite similar enzyme levels to the mother, review finds (Biomedicines 2021)
- eMERGE Network study fails to replicate the CETP-triglyceride association found in prior smaller studies (BMC Med Genomics 2021)
- ApoC-II and apoC-III move from VLDL preferentially into larger HDL3 particles, and a CETP inhibitor does not change this transfer (Biol Chem 2021)
- Gut metabolite TMAO shows no link to genetically determined CETP levels in coronary artery disease patients (Sci Rep 2020)
- QSAR models predict CETP inhibitory potency of 108 oxazolidinone derivatives (SAR QSAR Environ Res 2020)
- A review commits to covering PCSK9, ANGPTL8, sortilin and CETP as candidate molecular links between psoriasis and cardiometabolic syndrome risk (Int J Mol Sci 2020)
- Liver-humanized mice show a human-like cholesterol lipoprotein profile without needing CETP (Hepatology 2020)
- Higher preoperative plasma CETP is one of four protein signals linked to atrial fibrillation after bypass surgery (J Thorac Cardiovasc Surg 2021)
- Calcitriol raises CETP levels alongside HDL-C in a rabbit model of atherosclerosis (Int J Vitam Nutr Res 2019)
- Ursolic acid ester derivatives designed as novel plant-based CETP inhibitors (Bioorg Med Chem Lett 2019)
- QSAR modelling and molecular docking chart a path to new CETP inhibitor compounds for coronary heart disease (J Biomol Struct Dyn 2020)
- A simple diffusion-like mathematical model estimates how much triglyceride CETP shuttles between lipoproteins from routine lipid measurements (BMC Syst Biol 2019)
- Multi-model computational study of 140 benzoxazole compounds maps the structural requirements for potent CETP inhibition (J Biomol Struct Dyn 2019)
- A review of PLTP and CETP in atherogenesis weighs the mixed record of CETP inhibitors against open questions about PLTP (Adv Clin Exp Med 2018)
- CETP inhibitors do not appear to raise new-onset diabetes risk unlike LDL-receptor-acting drugs (J Cardiovasc Pharmacol Ther 2018)
- Saffron-derived crocin raises CETP levels within treated patients, but not significantly versus placebo (ARYA Atheroscler 2017)
- Cryo-electron tomography reveals a polyhedral, not spherical, 3D structure for VLDL particles (J Lipid Res 2016)
- A new cycloalkene-scaffold CETP inhibitor raises HDL cholesterol in hamsters (Eur J Med Chem 2016)
- Molecular dynamics simulations support a tunnel mechanism for lipid transfer by CETP (J Biol Chem 2016)
- Molecular dynamics studies show small-molecule CETP inhibitors act by physically blocking the lipid transfer tunnel (J Phys Chem B 2016)
- All-atom simulations show a complete cholesteryl ester can pass through the CETP tunnel at a physiologically realistic rate (J Biol Chem 2016)
- Novel benzylaminopropionanilide CETP inhibitors raise HDL and lower LDL in hamsters (Bioorg Med Chem 2016)
- Policosanol combined with reconstituted HDL outperforms anacetrapib at inhibiting CETP in a hyperlipidemic zebrafish model (Rejuvenation Res 2016)
- CETP and PLTP exemplify how BPI-like TULIP proteins form tubular channels to exchange lipids between lipoprotein particles (Biochim Biophys Acta 2016)
- A structure-guided approach discovers a novel indoline series of CETP inhibitors (ACS Med Chem Lett 2016)
- Review highlights zebrafish, which retain a cetp ortholog, as an emerging model for dyslipidaemia research (Front Endocrinol (Lausanne) 2016)
- Electron microscopy shows CETP binds HDL through hydrophobic surface interactions, not protein contacts (Sci Rep 2015)
- Review highlights that CETP inhibitors lower blood glucose alongside raising HDL cholesterol (Front Pharmacol 2015)
- Plant-produced chimeric protein targeting ApoB100 and CETP epitopes elicits antibody responses in mice (Mol Biotechnol 2014)
- Atomistic simulations reveal how CETP penetrates HDL via a tryptophan anchor and phenylalanine barrier (J Lipid Res 2015)
- Dalcetrapib, but not anacetrapib, raises plasma and liver levels of the dietary antioxidants lutein and zeaxanthin (Lipids 2014)
- New synthesis route scales a polycyclic CETP inhibitor to multikilogram quantities (Org Lett 2014)
- Diphenylpyridylethanamine-based aminoheterocycles optimised as CETP inhibitors with better metabolic stability (Bioorg Med Chem Lett 2014)
- Review asks why targeting HDL for cardiovascular protection has not delivered clinical benefit (J Cardiovasc Pharmacol 2013)
- Validated comparative QSAR modelling of 104 CETP inhibitors identifies key structural drivers of potency (Comput Biol Med 2013)
- Vitamin E tocotrienol supplementation lowered CETP activity and improved lipids in chronic hemodialysis patients (Vasc Health Risk Manag 2013)
- Fluorinated diphenylpyridylethanamine derivatives balance metabolic stability and CETP potency (Bioorg Med Chem Lett 2012)
- CETP variant rs5882 is one of only four significant SNP predictors of plasma homocysteine among 64 tested in healthy adults (J Nutr 2012)
- Quinoline-3-carboxamide derivatives reach 80.1 percent CETP inhibitory activity in newly designed series (Molecules 2012)
- LDL apheresis transiently reduces CETP-mediated cholesteryl ester transfer and cholesterol efflux capacity in familial hypercholesterolemia (J Lipid Res 2012)
- CETP-driven cholesteryl ester enrichment of apoB particles is exaggerated in type 1 diabetes (Eur J Clin Invest 2012)
- Chinese medicine preparation SUB885C cuts CETP activity 74% and raises HDL-C in ApoE*3Leiden.CETP mice (PLoS One 2012)
- Review synthesises structural and biophysical evidence for how CETP moves lipids between HDL and LDL (Biochem Soc Trans 2011)
- Natural compound isolated from ginger rhizome inhibits CETP with an IC50 of 35 micromolar (Arch Pharm Res 2011)
- New biphenyl oxazolidinone CETP inhibitor scaffold reaches sub-100 nanomolar potency (ACS Med Chem Lett 2011)
- Review notes CETP transgene expression normalizes hepatic HDL cholesteryl ester delivery in humanized SR-BI knockout mice (World J Gastroenterol 2010)
- Chromanol derivatives emerge as a novel class of orally active CETP inhibitors suitable for clinical development (Bioorg Med Chem Lett 2011)
- 2-Arylbenzoxazole CETP inhibitors raise HDL cholesterol in cynoCETP transgenic mice (Bioorg Med Chem Lett 2011)
- Lead biphenyl CETP inhibitor 12d significantly raises HDL in a transgenic mouse model (Bioorg Med Chem Lett 2010)
- Lead benzylamino-methanone compound achieves 30 percent CETP inhibition at 10 micromolar (Molecules 2010)
- Review links apoB signal-peptide and CETP B1B1 combination to lower VLDL apoB secretion in obese men (Curr Opin Lipidol 2010)
- Novel tetrahydrochinoline derivatives yield a potent CETP inhibitor with favourable pharmacokinetics for clinical development (Bioorg Med Chem Lett 2010)
- Pharmacophore and QSAR modelling identifies new CETP inhibitor leads including NSC 40331 at 6.5 micromolar (Eur J Med Chem 2010)
- A new benzoxazine class of CETP inhibitors raises HDL cholesterol in transgenic mice and hamsters (Bioorg Med Chem Lett 2010)
- Lead 2-arylbenzoxazole compound inhibits CETP with an IC50 of 28 nanomolar (Bioorg Med Chem Lett 2009)
- Improved asymmetric synthesis route delivers a potent tetrahydroquinoline CETP inhibitor without a hazardous aryltin reagent (Org Lett 2009)
- Review surveys CETP's role in lipid metabolism and the state of small-molecule inhibitor development for raising HDL-C (Curr Top Med Chem 2009)
- Long-term danazol use lowers CETP mass without significantly affecting HDL cholesterol or atherosclerosis markers (Clin Ther 2008)
- ANGPTL3 abnormalities outnumber CETP abnormalities in Japanese hyperalphalipoproteinemic subjects (Clin Chim Acta 2008)
- 3D-QSAR modelling of 61 dibenzodioxepinone and dibenzodioxocinone compounds maps the structural features driving CETP inhibitory potency (Molecules 2008)
- Review weighs conflicting evidence for CETP as a pro- versus antiatherogenic therapeutic target (Expert Opin Ther Targets 2008)
- Array synthesis optimizes a high-throughput screening hit into a novel 2-arylbenzoxazole CETP inhibitor series (Bioorg Med Chem Lett 2008)
- A review revisiting a 40-year-old study names the CETP, VLDL-triglyceride, and hepatic lipase cluster as drivers of atherogenic HDL and LDL remodeling (Rom J Intern Med 2008)
- Review surveys a CETP-inhibiting vaccine among emerging anti-atherosclerotic vaccine strategies (Cardiol Rev 2008)
- Rosuvastatin lowered CETP activity and mass while raising HDL-C in metabolic syndrome patients (Atherosclerosis 2008)
- 2D and hologram QSAR models of 85 trifluoro-aminopropanol CETP inhibitors identify key structural drivers of potency (Bioorg Med Chem 2007)
- New fluorescence quencher triples the signal window of a CETP activity assay for large-scale drug screening (Anal Biochem 2007)
- Tetrazole and ester substituted tetrahydroquinoxalines emerge as a potent new class of CETP inhibitors (Bioorg Med Chem Lett 2007)
- Mini-review places CETP-mediated cholesteryl ester transfer within the broader reverse cholesterol transport pathway (Rom J Intern Med 2007)
- Mapping the CETP gene reveals seven distinct linkage blocks and yields an optimal set of eleven tagging SNPs for future association studies (Ann Hum Genet 2006)
- Review surveys recent findings on plasma lipid transfer proteins including CETP's role in HDL delivery and coronary risk (Curr Opin Lipidol 2006)
- Review traces how statins raise HDL cholesterol partly via a secondary reduction in CETP activity (Curr Atheroscler Rep 2006)
- A review proposes that CETP is one of four enzymes that remodel spherical HDL into the lipid-poor apoA-I needed for reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2006)
- Omega-3 fatty acid intake correlates with lower CETP activity in Tunisian women with type 2 diabetes (Nutr Metab Cardiovasc Dis 2006)
- Alcohol abuse alters CETP glycosylation, lowering its surface charge and likely its activity (Alcohol Alcohol 2006)
- SR-BI processing of HDL2 segregates apoA-I and apoA-II catabolism into distinct particles, independent of CETP, LCAT, or PLTP (J Lipid Res 2005)
- Optimized dibenzodioxocinone derivatives yield low-nanomolar CETP inhibitors stable in rat plasma (Bioorg Med Chem Lett 2005)
- LXR agonists raise LDL cholesterol in CETP-expressing hamsters and monkeys, an effect invisible in CETP-lacking mice (J Lipid Res 2005)
- CETP localizes to germinal centre B cells and their neoplastic lymphoma counterparts (Histopathology 2004)
- Electron-withdrawing substituents boost potency in a new propanethioate class of CETP inhibitors, reaching 50 percent inhibition at 2 micromolar (Bioorg Med Chem Lett 2004)
- Postprandial chylomicrons are up to 40 times more potent than VLDL at accepting cholesterol from LDL and HDL via LCAT and CETP (J Lipid Res 2004)
- Chemically induced P-407 mouse model of hyperlipidemia indirectly raises CETP activity while directly inhibiting lipoprotein and hepatic lipase (J Cardiovasc Pharmacol 2004)
- A review names CETP among three plasma factors that release lipid-poor apoA-I from HDL during remodeling, the key acceptor for ABCA1-mediated cholesterol efflux (Arterioscler Thromb Vasc Biol 2004)
- A review of HDL structure names CETP among four proteins, alongside LCAT, SR-BI, and ABCA1, that remodel HDL particles in vivo (Front Biosci 2003)
- Plant stanol ester spread lowers CETP mass alongside LDL cholesterol and oxidized LDL in a Japanese trial (Nutrition 2003)
- Men who respond strongly to dietary cholesterol also show higher CETP activity during high-egg feeding, suggesting boosted reverse cholesterol transport (J Nutr 2003)
- ApoA-I-free HDL-LpE particles are more than twofold more abundant in CETP-deficient subjects and efflux cholesterol as effectively as apoA-I (J Lipid Res 2003)
- New statistical method for analyzing gene haplotypes is validated using CETP variants and HDL cholesterol data from the REGRESS trial (Ann Hum Genet 2003)
- Only atorvastatin, not fenofibrate, lowers CETP activity in metabolic syndrome patients despite both lowering triglycerides (Diabetes 2003)
- Review explains how CETP-mediated cholesteryl ester transfer links low HDL-C to high triglycerides in insulin resistance and type 2 diabetes (Clin Lab 2003)
- Estradiol fatty-acid esters transfer from HDL to LDL via a CETP-associated process, a review finds, while their broader physiologic roles remain under study (Cardiovasc Res 2002)
- CETP inhibitory peptide P28 selectively blocks HDL-to-LDL but not HDL-to-HDL cholesteryl ester transfer (Lipids 2002)
- Thyroid hormone excess doubles CETP activity and accelerates HDL clearance in transgenic mice (Metabolism 2001)
- A review names PLTP and CETP as joint targets of the nuclear receptors FXR and LXRalpha, central to reverse cholesterol transport (Curr Pharm Des 2001)
- Heterozygous CETP D442G carrier shows apolipoprotein E trapped in HDL at triple the level of other carriers (Clin Chim Acta 2000)
- No CETP mass is detected in human cerebrospinal fluid, unlike LCAT and phospholipid transfer protein (J Lipid Res 2000)
- Red wine, not alcohol alone, raises HDL cholesterol and cholesterol efflux capacity 7% in young men, without altering CETP (Nutr Metab Cardiovasc Dis 2000)
- Atorvastatin cuts CETP activity by up to 26.4% while reshaping apolipoprotein distribution in hypertriglyceridemia (Metabolism 2000)
- A domino Mukaiyama-Michael/Michael/Aldol cyclization efficiently builds pentasubstituted arene cores for potent CETP inhibitors (Angew Chem Int Ed Engl 1999)
- A review by the LTIP discoverer surveys how CETP expression, atherogenesis and lipid transfer inhibitor protein activity interconnect (Curr Opin Lipidol 1999)
- A retinoic acid receptor element is identified in the human CETP gene promoter (Biochem Biophys Res Commun 1999)
- Erabulenols A and B, new fungal metabolites from a soil Penicillium isolate, inhibit human CETP with IC50 values of 47.7 and 58.2 micromolar (J Antibiot (Tokyo) 1998)
- A fungal depsipeptide, SCH 58149, shows weak CETP inhibitory activity with an IC50 of 50 micromolar (Bioorg Med Chem Lett 1998)
- Bezafibrate, but not gemfibrozil, significantly lowers cholesteryl ester transfer activity in type IIb hyperlipoproteinaemia (Atherosclerosis 1998)
- Probucol regresses established aortic plaques in hyperlipidemic rabbits and significantly raises CETP activity, likely via antioxidant action (Atherosclerosis 1998)
- Triglyceride enrichment, not CETP alone, is what makes PLTP remodel HDL into larger and smaller particles (J Lipid Res 1998)
- A review names LCAT, hepatic lipase, and CETP as the key HDL-remodeling enzymes suppressed during cytokine-driven hyperlipidemia (Z Ernahrungswiss 1998)
- Swapping dietary palmitic acid for trans elaidic acid raises CETP activity and lowers HDL more in cebus monkeys (J Nutr 1997)
- A review identifies LCAT and CETP as the two key enzymes driving reverse cholesterol transport, though its antiatherogenic role remains unproven (Can J Cardiol 1996)
- A review names CETP among four enzyme mutations that reshape HDL particle size and regulate HDL cholesterol and apoA-I levels (Curr Opin Lipidol 1996)
- Polyacetylene compounds isolated from Korean ginseng roots inhibit human CETP (Chem Pharm Bull (Tokyo) 1996)
- Ethanol oxidation, not reduced CETP synthesis, explains alcohol's redistribution of CETP among lipoproteins (ATVB 1996)
- The ApoA-IHelsinki mutation lowers HDL cholesterol and cuts CETP activity by 25% in a Finnish kindred (ATVB 1995)
- New monoclonal-antibody immunoassays quantify CETP mass down to nanogram levels in plasma and cell culture (J Lipid Res 1995)
- The first competitive ELISA for CETP detects 1 nanogram per well with a coefficient of variation under 6% (Clin Chim Acta 1994)
- Review weighs the shuttle versus ternary-complex models for how CETP transfers lipids and flags evidence for a pro-atherogenic role (Clin Exp Pharmacol Physiol 1994)
- A review names CETP, LCAT, and lipases as the enzymes driving HDL subclass interconversion in mature HDL formation and reverse cholesterol transport (Curr Opin Lipidol 1994)
- A fast two-site immunoassay measures CETP mass in 6 hours with under 9% assay variability (Clin Chem 1994)
- CETP activity peaks in the second trimester of pregnancy and tracks HDL-triglyceride accumulation (Clin Biochem 1994)
- Cholesterol esterification is 16% slower in Alzheimer's disease, echoing earlier findings in Down's syndrome (Mech Ageing Dev 1994)
- Rabbit liver's nonparenchymal cells express more CETP mRNA than the parenchymal cells that dominate most other lipid genes (J Lipid Res 1993)
- Horses show no significant cholesteryl ester transfer protein activity despite having VLDL, LDL, and HDL (Comp Biochem Physiol B 1993)
- A polyclonal-antibody immunoradiometric assay detects CETP down to 0.1 nanograms with under 9% variability (J Lipid Res 1993)
- HepG2 cells secrete an unidentified factor that reshapes nascent HDL into HDL2b particles, with cholesteryl ester transfer detected but not attributable to CETP (J Lipid Res 1993)
- A review names LCAT and CETP as the joint enzymatic drivers of reverse cholesterol transport from tissues to the liver (J Am Osteopath Assoc 1992)
- A symposium report names LCAT and CETP as joint mediators of the Glomset reverse cholesterol transport hypothesis, still clinically unproven (J Lipid Res 1990)
- Unlike LBP, its structural relatives BPI, CETP and PLTP show no expression difference in necrotizing enterocolitis, isolating LBP as the disease-associated biomarker (J Pediatr Surg 2026)
- A wild valerian relative and beta-sitosterol inhibit CETP and lower lipids in triton-induced hyperlipidemic rats (Food Sci Nutr 2024)
- Walnut kernel polyphenols are proposed to improve metabolic syndrome partly by inhibiting SREBPs, PCSK9 and CETP (Food Sci Nutr 2024)
- A systematic review finds no clear link between CETP genetic variation and intestinal cholesterol absorption (Prog Lipid Res 2022)
- Three months of water-based exercise moved body weight in obese older men but left CETP activity and blood lipids unchanged (Diabetes Metab Syndr 2021)
- Simvastatin lowers HMGR but not CETP expression in bovine adipocytes (Anim Biotechnol 2020)
- CETP genotype does not modify how DHA supplementation lowers triglycerides, randomized feeding trial finds (Lipids 2018)
- Structural study designs a self-binding CETP peptide stabilized by pi-pi stacking and halogen bonding (Bioorg Chem 2016)
- QSAR models guide design of twelve new diphenylpyridylethanamine CETP inhibitors (Bioorg Med Chem Lett 2015)
- New diterpenes isolated from Engleromyces goetzii fungus show CETP inhibitory activity (Nat Prod Bioprospect 2015)
- LCAT and CETP activity track with disturbed HDL and triglyceride-rich lipoprotein composition after kidney transplant (Cell Biochem Biophys 2013)
- New tetrazolyl tetrahydroquinoline CETP inhibitors raise HDL cholesterol in a transgenic mouse model (Bioorg Med Chem Lett 2012)
- Xanthohumol from hops shows the strongest CETP-inhibitory activity among screened plant chalcones (Food Chem 2012)
- SAR study on the central phenyl ring of biphenyl oxazolidinone CETP inhibitors finds analogs matching anacetrapib in potency (Bioorg Med Chem Lett 2012)
- Saccharin-fed zebrafish show elevated CETP activity while aspartame-fed zebrafish suffer acute deaths under high-cholesterol diet (Food Chem Toxicol 2011)
- Review names CETP as one of only two candidate genes for lipid response to exercise training, despite roughly 100 inconsistent studies (J Appl Physiol 2011)
- A decade-spanning review narrows thirty cholesterol-lowering drug targets to six for detailed chemical and mechanistic analysis, including CETP inhibitors (Curr Med Chem 2011)
- Molecular docking maps the hydrophobic P1/P2 binding pockets used by trifluoro-aminopropanol CETP inhibitors (J Mol Model 2011)
- Modifying the alpha-alkoxyamide moiety of arylbenzoxazole CETP inhibitors yields an orally bioavailable lead (Bioorg Med Chem Lett 2010)
- Plasma CETP and PLTP levels are unchanged in end-stage renal disease despite HDL abnormalities (Nephrol Dial Transplant 2009)
- CETP levels track with bile acid concentration in children with Alagille syndrome cholestasis (Atherosclerosis 2008)
- CETP activity correlates with insulin resistance and leptin in obese subjects, but not independently of other factors (Metabolism 2007)
- Novel LCAT mutation in a Polish family leaves CETP activity at the low end of normal (Atherosclerosis 2006)
- CETP activity correlates with HDL triglyceride enrichment and reduced antioxidant capacity in postmenopausal women (Atherosclerosis 2004)
- Egg-induced cholesterol hyperresponders show higher CETP and LCAT activity than hyporesponders (Metabolism 2004)
- CETi-1, AVANT Immunotherapeutics CETP-targeting vaccine, entered Phase II trials for hypercholesterolemia and atherosclerosis by 2001 (Curr Opin Investig Drugs 2004)
- Cholesterol feeding boosts CETP mRNA up to 5-fold via LXRalpha in rabbits before FXR activation catches up (J Lipid Res 2003)
- Single endotoxin dose triggers rapid LDL decline and slower CETP activity loss in healthy volunteers (J Lipid Res 2003)
- The inability of rat serum to transfer dietary oxidized cholesterol to LDL/HDL points to CETP as the mediator (J Lipid Res 2003)
- Egg-diet hyperresponder premenopausal women show higher CETP alongside apoB and apoC-III (J Am Coll Nutr 2002)
- A review by Barter and Rye finds continuing conflict in the evidence on whether cholesteryl ester transfer protein is atherogenic or anti-atherogenic (Curr Opin Lipidol 2001)
- Ferroverdins B and C, natural CETP inhibitors from Streptomyces, are elucidated as iron complexes of nitroso-hydroxybenzoate ligands (J Antibiot (Tokyo) 1999)
- Mapping a monoclonal antibody's CETP epitope explains why it blocks triglyceride but not cholesteryl ester transfer (J Lipid Res 1999)
- Low-dose testosterone in women lowers HDL cholesterol without changing CETP activity (Clin Endocrinol 1998)
- Erabulenols A and B, fungal CETP inhibitors, share a phenalenone-tetrahydrofuran core, with a hydroxy-methylketonyl benzyl group distinguishing erabulenol B (J Antibiot (Tokyo) 1998)
- A new 1H NMR method tracks CETP-driven lipid transfer in lipoprotein mixtures without ultracentrifugation (NMR Biomed 1997)
- CETP mass and cholesteryl ester transfer are unchanged in normotriglyceridemic type II diabetics, fasting or fed (Atherosclerosis 1996)
- Recombinant cynomolgus monkey CETP is expressed and purified 176-fold from CHO cells for structural study (J Protein Chem 1995)
- Triazine-dye affinity chromatography purifies human CETP up to 100,000-fold from lipoprotein-depleted plasma (Protein Expr Purif 1994)